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ABSTRACT
Magnetic nanoparticles (MNPs) have been investigated in tissue engineering
applications to provide in situ imaging, drug delivery, and tissue patterning, but direct
and prolonged interaction between cells and MNPs can have adverse effects on cell
function. Therefore, methods which reduce or limit the interaction of MNPs with cells, or
utilize more biocompatible MNP-based strategies will improve upon the commonly used
iron oxide MNPs. We investigated a variety of methods to improve upon the use of
MNPS in tissue engineering.
Cell aggregates, or spheroids, have been used as tissue engineered building blocks
that can closely mimic the native three-dimensional in vivo environment. Current
strategies incorporating MNPs into tissue engineering often involve cellular uptake,
however, which can induce adverse effects on cell activity, viability, and phenotype, and
should therefore be avoided. Here, we report a Janus structure of magnetic cellular
spheroids with spatial control of MNPs to form two distinct domains: cells and
extracellular MNPs. This separation of cells and MNPs within magnetic cellular
spheroids had no adverse affects on long-term viability or cellular phenotype, allowing
for the magnetic manipulation and fusion into controlled patterns and complex tissues.
Iron oxide NPs are the most common MNP in biomedical applications, but these
MNPs often require complex surface modifications to improve their biocompatibility. We
report the preparation of magnetoferritin NPs, a biological MNP, capable of serving as a
biological alternative to iron oxide MNPs. Magnetoferritin NPs were incorporated into
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Abstract (continued)

three-dimensional cellular spheroids with no adverse effects on cell viability and were
capable of magnetic force assembly into fused tissues.
Additionally, the ideal nanomaterial will remain stable for a sufficient amount of
time to accomplish its desired task, and then rapidly degrade once that task is completed.
We report the use of surface modifications to accelerate iron oxide MNP degradation
mediated by polymer encapsulation in polymers with different degradation rates:
poly(lactide) (PLA) or copolymer poly(lactide-co-glycolide) (PLGA). Results
demonstrated that the degradation of MNPs can be controlled by varying the content and
composition of the polymeric nanoparticles used for MNP encapsulation (PolyMNPs).
These PolyMNPs maintained a high viability compared to non-coated MNPs, and are
also useful in magnetic force assembly into fused tissues. The presented results highlight
multiple strategies which can improve upon the biocompatibility of MNPs in tissue
engineering applications.
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CHAPTER 1
BACKGROUND
SMALL DIAMETER VASCULAR GRAFTS
Each year, thousands of patients are unable to receive organ implants due to a
shortage of available donor organs. The field of organ transplantation to replace or repair
damaged tissues is dependent solely upon the number of available donor organs, with the
number of waitlisted patients increasing annually [1]. The American Heart Association
estimates that the total number of cardiovascular operations and procedures increased
28% from 2000 to 2010, with 7,588,000 procedures performed in 2010, ranking
cardiovascular disease as the highest among all disease categories in hospital discharges
[2]. For vascular engineering, the majority of vascular diseases and failures occur in
blood vessels less than 6 mm in diameter [3]. Though autologous vascular tissue from
the host is the most preferable solution when available, it is estimated that 30% of
patients with vascular problems lack sufficient vasculature for autologous replacement
due to abnormalities or damaged tissues [4]. The use of commercially employed grafts is
currently limited to autografts, allografts, and xenografts, as well as synthetic ePTFE and
Dacron.

However, human clinical trials have been recently begun for engineered

vascular grafts made from novel polymers [5] and cell sheet technologies [6]. As the
forces experienced by the different types of vessels vary, a primary challenge in tissue
engineering

vascular

grafts

involves

matching

native

mechanical

properties.

Additionally, the different vessel types contain diverse cellular and extracellular matrix
(ECM) compositions that mediate their mechanical properties and function. Therefore, a
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variety of approaches have been investigated for the assembly of a small diameter
vascular graft capable of restoring native functionality that also integrates with the host to
negate the need for eventual graft replacement.

These strategies, along with their

shortcomings and potential solutions, are detailed in the following sections.
1.1. Biological Vascular Grafts
1.1.1. Autograft
For small diameter blood vessel replacements, arterial and venous autografts are
typically the optimum procedure used (Figure 1.1) [7]. The internal mammary artery
(IMA) and radial artery are preferred for coronary artery bypass grafts [8]. However, for
lower limb and peripheral bypass procedures, saphenous vein grafts (SVGs) are
commonly used. The predictors of autograft patency include the size of recipient vessel
(length and diameter) [9], the particular disease of the patient, and the methods used to
preserve the grafts [10]. Though cold storage has been associated with long term graft
patency, primarily attributed to its preservation of the inherent endothelial function, these
grafts are still susceptible to common modes of failure such as atherosclerosis and intimal
hyperplasia [11, 12]. Additionally, it is estimated that 30% of patients requiring vascular
replacement lack sufficient vasculature for grafting due to damaged vessels [4], typically
attributed to inadequate quality of vessels from either prior disease due to a lack of
vasculature due to prior use [13].
The use of autografts over other grafts is primarily due to their high long-term
patency rates. Goldman et al. compiled data from 1254 patients analyzing long-term
results of IMA and SVGs for coronary artery bypass grafts [14]. Subsequent analysis
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confirmed the differences in patency between the two autologous sources, with overall
patency rates of 61% for SVGs and 85% for IMA grafts at 10 years. These results further
confirm the difficulty associated with small diameter vascular replacement, as autografts
still encounter difficulties.
1.1.2. Allograft
Though the high availability and easy storage of allografts (via cryopreservation)
permit their quick use, difficulties arise due to inabilities to tailor matrix content and
dimensions (Figure 1.1). Additionally, they have an inherent risk of viral transmission
[15], are subject to breakdown from processing [16], and also exhibit poor long-term
patency [17, 18].
Though various studies have been performed to analyze the effectiveness of
cryopreserved commercial allografts, results have revealed contradicting conclusions
based on sample size, methods of preservation, patient population, and use of
pharmacological agents [19]. In their study of 240 cryopreserved allografts implanted in
lower limbs using commercial CryoLife Cryografts over the course of 10 years, Farber et
al. found these allografts to be characterized by poor primary patency, with rates of only
83% at 1 month, 50% at 6 months, 30% at 12 months, and 18% at 24 months [20].
Additionally, mortality rates were higher than that reported by other studies, in which
only 72% patients remained alive after year one with a subsequent decrease to 69% at the
end of year two. Causes of graft failure included thrombus formation, wound infection,
seroma formation, and aneurysm [17, 19, 20]. Though results suggest that these grafts
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may be sufficient to prevent immediate limb loss, they are ineffective as a long-term
replacement strategy [19].
1.1.3. Xenograft
Vascular xenografts can come from tissues other than blood vessels, including the
submucosa of the small intestine (Figure 1.1) [21, 22]. Although readily available,
xenografts are not commonly used in vascular replacements due to immunorejection, low
patency rates [23], and the need for additional treatments to reduce thrombotic responses
[21]. One method for improving xenograft function entails in vivo endothelialization, in
which the scaffold is implanted subdermally within the host and populated with
autologous cells prior to desired use [24].
Commercially available xenografts for vascular replacements are also available.
Clinical results have demonstrated the ArteGraft’s superiority as an AV access graft
compared to ePTFE grafts, with primary patency rates at one year of 60.5% compared to
10.1% of synthetic grafts [25]. However, clinical trials comparing the ProCol (collagen
cross-linked vascular solution derived from the bovine mesenteric vein) to ePTFE grafts
for AV access grafts showed low patency (1 year primary patency of 36% and 28% for
ProCol and ePTFE, respectively) [23].

4

•High longterm patency

•Inability to
tailor
dimensions

•Autologous
source

•Biologicallybased

Internal
Mammary
Artery

•Limited
supply

Saphenous
Vein

•Inability to
tailor matrix
contents
•Risk of viral
transmission

•Long shelf-life
•Mechanical
breakdown
from
processing

•Readily
available
•Biologicallybased
Xenograft

rte
ry

•Secondary
surgical site

Schematic

lA

•Biologicallybased

•Readily
available

Allograft

Cons

dia

Autograft

Pros

Ra

Graft

Decellularize
& Cryopreserve

•Risk of
immunorejection
•Require graft
modifications

•Long shelf-life
•Poor longterm patency
Decellularize
& Cryopreserve

Target Site

Harvest Site

Figure 1.1. Biological Vascular Grafts. Grafts can be harvested from a variety of
sources, including the patient (autograft), another person (allograft), or an animal
(xenograft). Though autografts are currently the best method for small diameter vascular
grafts, patients may lack sufficient vasculature to harvest, in which case other grafts may
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be used [26]. Allografts and xenografts both require treatment to decellularize the
vessels prior to use, which introduces problems such as mechanical breakdown and the
inability to tailor vessel dimensions or composition [27, 28].
1.2. Polymeric Engineered Vascular Grafts
1.2.1. ePTFE and Dacron
The limited availability of autologous conduits has led to a widespread use of
synthetic grafts. The main materials for engineered synthetic grafts include woven
polyethylene terephthalate (PET), more commonly known as Dacron, and expanded
polytetrafluoroethylene (ePTFE). The use of either ePTFE or Dacron has shown no
significant differences regarding patency between each in small diameter graft
applications, with three-year patency rates of approximately 60% for both [29, 30].
Although these grafts have been used successfully in large diameter vascular
grafts, low long-term patency rates render them ineffective in small diameter settings, a
phenomenon that is often attributed to compliance and mechanical mismatch [7-9]. The
primary deficiencies of these materials include an increased rigidity compared to native
vasculature [10] and a lack of endothelial lining (Figure 1.2) [11-16]. In small diameter
applications, this can cause thrombus formation often attributed to compliance mismatch,
which in turn results in graft failure [10, 17, 18]. Research has been performed to
improve small diameter synthetic grafts via functionalization to promote cell adhesion
using a variety of biomolecules, including fibronectin [19, 22], collagen [22], cell
adhesion peptide sequences [21, 23, 24], and growth factors [25, 31-33]. Results have
shown improved cell adhesion compared to bare grafts, thereby potentially improving
graft functionality. The risk factors inherent in using these small diameter ePTFE and
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Dacron grafts include age, gender, smoking, hypertension, and graft diameter [29].
Typically used in large diameter applications, these grafts have a low patency in small
diameter applications below the knee [7-9], with larger diameter grafts (7-8 mm
diameter) demonstrating higher three-year patency rates than their smaller (5-6 mm
diameter) counterparts.
1.2.2. Biodegradable Polymeric Scaffold
A variety of polymers have been analyzed for use in the fabrication of engineered
vascular grafts due to their high availability, low cost, and ability to be fabricated into
controlled shapes and dimensions. Biodegradable scaffolds have been increasingly used
as vascular grafts that will initially provide mechanical support while promoting tissue
infiltration and growth, eventually being replaced entirely by native tissue (Figure 1.2).
Common biodegradable polymers investigated for use in vascular engineering include
polyglycolic acid (PGA) [34], polyurethanes (PUs) [35], polycaprolactone (PCL) [5], and
polylactic acid (PLA) [36-39]. One of the most often used methods for the fabrication of
biodegradable polymeric vascular grafts is electrospinning [40-44]. This scalable and
easily customized method allows for control of electrospun fiber diameter and
orientation, scaffold porosity, spatial location of heterogeneous graft components, and
graft material properties based on fabrication parameters. Compared to other nanofiber
fabrication techniques (e.g. drawing, template synthesis, temperature-induced phase
separation, and molecular self-assembly), electrospinning is advantageous because its
results are reproducible, scalable, continuous, and can be easily tailored to assemble
either micro-or nano fibers using the same experimental set-up with a variety of biologic
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and synthetic polymers [40, 45]. By controlling the nanofiber deposition, it is possible to
create electrospun vascular grafts that closely mimic the native extracellular matrix
scaffold within vessels, while also mediating cellular interactions and orientation within
electrospun grafts based upon such criteria as the diameter [46], porosity [47], and
surface topography of a given fiber [48].

Synthesis parameters, such as polymer

concentration (viscosity), jet radius, flow rate, electrical potential, solution conductivity,
and distance between nozzle and collector mediate fiber diameter and morphology and
can be tailored based on desired properties [45, 49, 50]. Altering these parameters
enables the creation of fiber diameters ranging in size from 50 nm up to 12 µm [51, 52].
Additionally, the porosity of electrospun scaffolds can be tailored to promote cell
infiltration, with pore sizes ranging in size from 2-465 µm and porosities up to 92% [53,
54]. Furthermore, the ability to fabricate multilayered scaffolds can be used to improve
graft biocompatibility and mechanical properties.

In their efforts to assemble an

electrospun bilayered scaffold with an inner layer of elastin, Wise et al. mimicked native
vascular structures by utilizing elastin and PCL. Elastin improved the biocompatibility
and interaction with blood and circulating cells. The inner elastin layer was surrounded
by an external layer of PCL, which provided scaffolds with mechanical support [55].
Other groups have demonstrated spatial control over fiber diameter and porosity,
successfully assembling grafts containing highly porous inner layers, which support cell
adhesion and infiltration, within the lumen and more dense external layers to provide
mechanical support [56, 57]. The ability to assemble tailored scaffolds that can closely
mimic the structure and scale of native ECM makes electrospun scaffolds a good
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candidate for small diameter vascular grafts. However, a strong understanding of how
scaffold properties (fiber diameter, porosity, copolymer orientation, fiber alignment)
mediate its interaction with the local biological environment and eventual biodegradation
must be established to optimize scaffold properties.
Polyglycolic acid (PGA) is one of the most commonly investigated polymers for
use in creating degradable vascular scaffolds due to its rapid degradation compared to
other polymers [34, 58]. As one of the fastest degrading polymers in biological
environments, PGA has shown limitations in maintaining long-term mechanical
properties, with studies demonstrating a complete loss of tensile strength in raw PGA
scaffolds after a three week incubation period in an aqueous environment [59]. However,
this loss of scaffold support is balanced by the additional strength of cell penetration and
proliferation, as well as ECM generation and secretion. Results have shown that samples
seeded with cells mechanically improve with culture time, demonstrating an almost fourfold increase in burst strengths between five and eight weeks in culture [59]. Another
interesting characteristic of PGA scaffolds is the in vitro dedifferentiation of smooth
muscle cells (SMCs) from PGA degradation byproducts [34, 59-61].

This

dedifferentiation of SMCs raises concerns for vascular failure, as intimal hyperplasia has
been correlated to the proliferation, dedifferentiation, and migration of SMCs into the
intima of vessels [62-64]. While biodegradable PGA vascular grafts have shown some
success in vivo, their rapid degradation and adverse effects related to degradation
byproducts hinder their use in small diameter vascular grafts.
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Polyurethanes (PUs), another common biodegradable polymer, have also been
investigated for use as a vasculature material. Though the viscoelastic compliant nature
of PUs is a suitable alternative polymeric vascular material for improving upon the low
compliance of other polymers, clinical results have been mixed, chiefly due to
degradation mechanisms and byproducts [35, 65]. Though PUs exhibited positive tissue
in-growth as well as reduced anastomotic hyperplasia in clinical trials [66, 67],
significant rates of thrombosis and infection [68], and variable rates of patency [67-70]
have also occurred with their use. Additionally, while poly(ether)urethanes (PEtU)
polymers have been used in medicine for 40 years, the thrombogenecity and aneurysm
formation within these polymers in various vascular solutions have resulted in clinical
outcomes that have been quite varied [65, 68, 71]. In their research to construct an
engineered vascular graft 5 mm in diameter, Soldani et al. used a PEtU macromolecule
containing poly(dimethyl siloxane) (PDMS), also known as silicone [35]. Porous
biodegradable PEtU grafts were implanted into an adult sheep carotid artery model and
compared to ePTFE grafts up to 24 months. The grafts contained two distinct regions, a
highly porous internal layer and a low porosity external layer. The use of a porous lumen
surface was also chosen based on previous studies that showed high porous luminal
surfaces are less thrombogenic than non-porous surfaces [72]. PEtU grafts maintained
patency up to 24 months, with grafts almost completely biodegraded and replaced by
fibro-connective tissue.

A noticeable radial enlargement was observed, however, a

potential sign of future graft failure via aneurysm. Additionally, the potential adverse

10

effects related to PEtU degradation byproducts may limit their clinical applications [73,
74].
Polymer selection is a critical for vascular engineering in that the mechanical
properties and the degradation kinetics of scaffolds can be tailored based upon polymer
properties. A fundamental property of polymeric vascular grafts is compliance and
elasticity, with polymers exhibiting a wide range of elastic modulus based on the polymer
selected. These polymers exhibit elastic modulus ranging from elastic PCL (4.98 MPa)
[75] to more rigid PLLA (56 MPa) [76]. Polymer mechanical properties are important in
that graft stiffness plays a key role in overall success, with differences in elastic modulus
leading to the formation of intimal hyperplasia [17].
Using a biodegradable copolymer, clinical trials have recently begun for the first
ever tissue-engineered blood vessel in the United States [77]. A copolymer of L-lactide
and !-caprolactone (50:50) was used to fabricate a polymeric scaffold supported with a
PGA woven fabric. Grafts exhibited approximately 80% porosity, with pore sizes from
20 to 100 µm, to allow for autologous bone marrow cell seeding and penetration prior to
implantation [58]. Although the implanted grafts cannot be classified as small diameter
(12-24 mm diameter), these results are still promising for use of polymeric scaffolds in
all vascular applications. In the median follow-up analysis of 5.8 years, no evidence of
aneurysm formation, graft rupture, graft infection, or calcification was present [5]. While
these results are promising for vascular grafts, the investigation into small diameter
applications using this strategy must be examined.
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While clinical trials are now underway on the first biodegradable polymer
vascular graft for large diameter applications, clinical trials for small diameter
biodegradable vascular grafts have yet to be undertaken. Data for biodegradable vascular
grafts in small diameter applications is often limited to short-term in vivo results (less
than six months), with potential problems often arising after this six month period.
Groups that have analyzed more long-term studies over six months have highlighted
some causes for concern regarding biodegradable vascular grafts. One group analyzed 2
mm electrospun PCL vascular grafts at various time points up to 18 months in rats to
determine their long-term fate [78]. Results showed that scaffolds maintained patency
and mechanical properties while allowing efficient endothelialization, but insufficient
regeneration was seen in the vascular wall over time. Endothelialization, cell invasion,
and neovascularization increased over a period of six months, but regressed at 12 and 18
months, leading to eventual calcification of grafts. Identical results have also been
observed in collagen based vascular grafts after six months in a canine model, with
evaluation performed up to 12 months [79]. In addition to this cellular regression,
biodegradable vascular grafts also have deficiencies related to degradation kinetics.
Specifically, the degradation rate of these grafts, as either mechanical failure or variations
in graft degradation kinetics, can lead to unpredictable graft failures. Overall, though
biodegradable vascular grafts have numerous advantages related to fabrication of
controlled structures, complications related to cellular regression and degradation kinetics
and byproducts must be elucidated and understood.
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Figure 1.2. Polymeric Vascular Grafts. Polymeric grafts can be separated into two
categories: permanent and biodegradable. Permanent polymeric grafts are made of
ePTFE and Dacron, and serve well in large diameter applications [29]. However, they
encounter problems in small diameter vessels, often attributed to mechanical mismatch
[10]. Biodegradable polymers serve initially as a mechanical support, but eventually
degrade and are replaced with native tissue. Difficulties often arise when attempting to
tune degradation kinetics, mechanical properties, and balancing degradation products [35,
80].
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1.2.3. Natural Polymers
Natural biopolymers such as collagen [81, 82], fibrin [83, 84], elastin [85],
chitosan [86, 87], and silk [88, 89] have also been investigated for use as vascular grafts.
Though the biological origin of these materials provide natural cell attachment sites and
improved tissue integration compared to synthetic polymers, purification and isolation of
these materials often makes them mechanically weak and expensive to produce [90].
These grafts can, however, be chemically modified or mixed with synthetic polymers to
improve their mechanical properties [55, 82, 91]. For example, Lee et al. evaluated
electrospun vascular grafts composed of collagen, elastin, and various polymers including
PLGA, PLA, PCL, and PLCL [92]. Results confirmed that mechanical properties could
be tailored via control over the synthetic polymer used, with the elastic modulus
increasing between pure collagen and elastin grafts (0.44 MPa) and grafts containing
PLGA (0.85 MPa) or PLA (2.08 MPa). Primarily due to their poor mechanical properties
when used alone, natural biopolymers function best in composite materials, in that they
reduce thrombogenecity, improve biocompatibility, and improve tissue integration
compared to pure synthetic polymers often used.

1.3. Scaffold-Free Vascular Grafts
Challenges related to polymeric vascular grafts have led to the development of
engineering strategies that allow cells to self-assemble and form vascular constructs
without the necessity of an architectural scaffold. Utilizing cell adhesion, self-assembly,
and the cell’s inherent ability to produce ECM, scaffold-free approaches provide a
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promising approach for the fabrication of small diameter vascular grafts. The primary
drawback of this technique, however, is the requirement for large quantities of autologous
cells, a costly and time-consuming endeavor [93]. However, various techniques have
shown great promise, with some already in human clinical trials [6]. An overview of
scaffold-free vascular grafts is provided in Figure 1.3.
1.3.1. Cell-Sheet Based Strategies
Cell-sheet technologies utilize autologous cells grown in vitro to synthesize a
sheet of living tissue that can be used to assemble a more complex tissue. Cells can be
grown on either thermoresponsive polymer films [94] or in special growth media
conditions [95] that stimulate ECM secretion, thereby causing the cells to create a solid
tissue sheet capable of manipulation. These sheets can then be layered sequentially to
control spatial cell location of multiple cell types within a tissue while maintaining both
cell interactions and ECM. These techniques have been applied to assemble myocardial
[96, 97], corneal [98, 99], oesophageal [100], and even dental [101] tissues which have
shown success in animal models.
Much research has been undertaken to develop cell-sheet based strategies for the
creation of scaffold-free vascular grafts [95, 102].

Specifically, Cytograft Tissue

Engineering recently published the results from Phase I & II clinical trials performed
using their patented Lifeline autologous cell-based vascular grafts.

L’Heureux and

colleagues developed a tissue engineered blood vessel from autologous cells with
mechanical properties comparable to native saphenous veins [95]. In 2009, nine patients
received Lifeline grafts as arteriovenous (AV) shunts for haemodialysis access, in which
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autologous fibroblasts and endothelial cells were obtained via biopsies and harvested in
vitro [6]. Overall, primary patency was maintained in 78% of the patients at one-month
post-implantation, and in 63% after six months.

Though the results of this study

demonstrated a potential fabrication technique for a complete biological and autologous
vascular graft, the long fabrication times (6-9 months) and high autologous cell quantities
required to produce such grafts currently mitigates their widespread use. Reducing both
the fabrication times and cell quantities must be accomplished prior to making such grafts
commercially viable [93].
Another company, Humacyte, is currently investigating the use of allogenic
SMCs to create a cell-derived acellular scaffold. Allogenic cells are seeded onto a PGA
scaffold and physically stimulated for two months to accelerate ECM secretion and
induce maturation using cyclic radial strain, followed by decellularization, which results
in a collagenous matrix. Results demonstrated high patency and a resistance to dilation,
calcification, and intimal hyperplasia in a baboon model as AV conduits [80], indicating
their viability as vascular grafts in cell-derived acellular scaffolds.
1.3.2. Aggregated Cell Constructs
Similar to cell-sheet based methods, this technique does not involve
decellularization that results in an ECM-based scaffold, but does utilize cellular selfassembly as a vascular graft. Using a circular agarose mold, Gwyther et al. successfully
fabricated SMC-based rings with inner diameters of 2, 4, and 6 mm [103]. Results
showed that individual rings, as well as stacked rings to form tubes, could be fabricated
in one to two weeks in static culture [104]. Mechanical testing to quantify ultimate tensile
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strength (UTS), stiffness, and toughness decreased (40% decrease in UTS in 6 mm rings)
for each sample as culture time increased due to necrosis in the core of the ring.
Additionally, mechanical properties of aggregated SMC rings were still much lower than
native arteries [105].
Other groups have utilized cellular spheroids to assemble vascular tissues. Kelm
et al. assembled human artery-derived fibroblasts and human umbilical cord vein
endothelial cells to form three-dimensional cellular spheroids [106].

Spheroids are

appealing for the assembly of complex tissues due to their ability to secrete ECM.
Results comparing 3D spheroids to 2D monolayers revealed a dramatic increase in the
expression of matrix-related gene transcripts such as collagen, fibronectin, laminin,
glycosaminoglycans (GAGs), and matrix metallopeptidases (MMPs).

Thousands of

individual spheroids were seeded in a custom-built bioreactor and subjected to both
dynamic flow and static conditions. Using 4,000-5,000 spheroids, a 5 mm long tube was
fabricated with a wall thickness of 1 mm in only 14 days. Although not yet proven in
vivo, strategies that utilize cells alone present a novel approach to vascular fabrication.
By allowing cells to self-assemble and secrete their own ECM, tissues can dynamically
adapt to meet required conditions.
Overall, scaffold-free vascular grafts have great potential in vascular engineering
due to their purely biologic nature. By allowing cells to self-assemble into required
densities and orientations, these vascular grafts can dynamically remodel to meet their
required needs. Additionally, these grafts can secrete their own ECM, providing further
mechanical support and dynamic remodeling. Challenges still exist regarding clinical
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applications, however. The harvesting, growth, and eventual assembly of engineered
grafts from autoglogous cells is both costly and time consuming, requiring months for the
complete fabrication of a functional vascular graft, which in turn prevents any scale-up of
this process.

Furthermore, while some techniques have demonstrated comparable

mechanical properties [107], most vascular grafts assembled using scaffold-free approach
cannot match the mechanical properties of native vasculature, increasing the risk of graft
failure due to mechanical mismatch. Consequently, elucidating the factors accelerating
graft assembly and maturation is imperative for optimizing these fabrication techniques.
1.3.3. Tissue Printing and Patterning
Attempts to simulate the orientation, density, and types of cells found within
native tissues have been thoroughly investigated as means to build engineered organs and
tissues via precise control and deposition of cells and ECM components [108]. In
embryonic development, specifically in a process known as morphogenesis, organs and
tissues self-assemble and align into complex networks of cells and ECMs to form a
particular tissue type [109]. Therefore, attempts to mimic this natural self-assembly offer
a promising approach in tissue engineering. Various techniques have been investigated
for cell and organ printing, including inkjet printing as well as “Bioink” deposition onto
“Biopaper”. These techniques can be viewed as an automated, computer-aided, rapid
prototyping technology capable of 3D tissue fabrication via individual cell or cell
aggregate deposition into controlled patterns.

Conventional cell-seeding techniques

involve a suspension of cells within a solution and subsequent incubation on either a
scaffold or surface.

This offers limited to no control of seeding density or spatial
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alignment, however. Additionally, these techniques are limited to monolayer deposition,
which is characterized by poor tissue infiltration. Therefore, additional approaches for
cell printing have been created that offer more precise control over conventional cell
suspension techniques, which also show much promise for the tissue printing of
engineered blood vessels (Figure 1.3) [110-112].
Inkjet printing has been used in many endeavors involving the printing of
biomolecules into desired patterns and orientations [113], including growth factors [114,
115], DNA [116, 117], proteins [118, 119], cells [120], and bacteria [121] using modified
inkjet technologies. Although mammalian cells are temperature-sensitive (250-350 °C),
the small time scale of heating (µs) is insufficient to significantly affect the surrounding
ink, therefore avoiding adverse effects on cell viabilty [120]. Analysis of the viability of
printed cells using inkjet printers vary, ranging from 50% up to 98% depending upon the
system configuration (thermal, piezoelectric, pressure-driven) and printing parameters
[119, 120, 122-124]. Reduced viability from inkjet printing is primarily due to either
shear stresses experienced during deposition or dehydration from droplet evaporation
[122].
The use of a cellular inkjet device is one such potential method for the rapid
fabrication of tissues [125]. Although 2D printing is now considered as an established
concept, sequential 3D cell printing remains the ultimate goal for truly comprehensive
tissue engineering. However, this technique has been demonstrated by multiple groups
using both cellular [126, 127] and acellular [128, 129] substrates. Cellular aggregates
have been successfully deposited on sequential layers of collagen and other
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thermoresponsive gels, with aggregates demonstrating successful fusion between gel
layers [126, 130]. Furthermore, acellular 3D alginate tubes have been printed using
inkjet technologies that are capable of withstanding physiological fluid flow through its
lumen [129].
Compared to inkjet strategies with cells in suspension, other strategies can print
bioink aggregates composed of cellular and acellular substrates. This bioink composition
can be controlled and optimized for desired tissue types, allowing for the “ink” to be
deposited in a maximum cell density, while also reducing cell damage related to other
printing strategies. Biopaper is a biocompatible gel that serves as a supporting
environment to hold the bioink aggregates in place to allow for fusion and formation of
the multicellular tissue.

Collagen [126, 131] and agarose [132] have already been

established as excellent supports (biopaper) for bioink fusion and aggregation. This
particular cellular printing technique, via printing and fusion of bioink aggregates, has
been successfully used to fabricate a scaffold-free tubular construct [132]. Here, the
biopaper is not an actual “sheet” of material, but rather an extruded cylinder of the
material itself.

Ink aggregates were formed via suspension of cells in a capillary

micropipette, creating a slurry mix capable of manipulation and handing. Cylindrical
bioink rods were then mechanically extruded using a custom bioprinter.

To form

spherical particles, these rods were mechanically cut into small segments which
demonstrated self-rounding capabilities. Agarose rods were also mechanically extruded
and used as supporting biopaper. Though collagen was initially used as the biopaper, an
uneven gelation in layer-by-layer deposition resulted in a noticeably imprecise product
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[131]. Additionally, collagen incorporation within the tube during fusion made removing
the biopaper template difficult, so agarose was instead used. Agarose rods (biopaper) and
spheroid aggregates (bioink) were carefully deposited in a variety of patterns in a layerby-layer fashion to form 3D structures. Samples were allowed to fuse for 5-7 days prior
to examination. Results demonstrated that tubes with diameters ranging from 900 µm up
to 2.5 mm could be successfully fabricated, as well as branched networks with varying
diameters. Furthermore, tubes could be patterned with different cell types to enable both
self-assembly and the formation of heterocellular constructs, which in turn permitted the
precise control over construct size, thickness, and pattern. Though these results have
demonstrated that formation of vascular grafts is possible, both mechanical properties and
in vivo studies have yet to be reported. Although promising, the use of spheroids can
prove difficult as fabrication techniques are problematic to upscale. Each vessel formed
requires a significantly large number of spheroids. For example, approximately 4,000
spheroids (300 µm diameter) were necessary to form a tube 10 cm long with a diameter
of 1.5 mm [132]. In that both the fusion and maturation of grafts is a time consuming
process, additional maturation via bioreactors and other techniques will likely be
necessary after initial fusion and formation. Finally, removal of the agarose rod from the
lumen of the vessel is done via manual pulling of the rod, therefore limiting its use in
branched network formation as well as potentially damaging cells along the lumen.
Xu et al. recently printed a 3D zigzag cellular tube using a custom bioprinting
system. Fibroblasts were suspended in sodium alginate to serve as a bioink that allowed
for precise spatial placement of bioink beads (in X, Y, and Z directions) that maintained
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cell viability post-printing.

The overhanging section of the printed tube collapsed,

rendering it unusable, however.

Although these results failed to improve upon the

mechanical challenges encountered in tissue printing, they demonstrate that bioprinting
systems can indeed be used to spatially control a bioink location within a 3D complex
tissue. This precise spatial control could be paired with other technologies, such as 3D
mapping of native tissues or embryonic development [133], to print patient-specific
tissues containing identical cellular and ECM components in their respective locations
and densities. The combination of these multiple technologies makes it possible for the
planned-printing of tissues to optimize fusion and self-assembly, based off results
gathered from studying embryonic and organ development. Overall, results suggest that
a comprehensive understanding of printing parameters, bioink deposition and fusion
properties, and tissue mechanical properties is necessary before a procedure for printing
both organs and tissues becomes possible.
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Figure 1.3. Scaffold-Free Vascular Grafts. Aside from permanent or degradable
polymeric scaffolds, vascular grafts are also fabricated using biological sources. These
techniques include cell sheets, cell aggregates, and tissue printing strategies. Methods
have been developed in which a sheet of cells is physically wrapped around a mandrel,

23

followed by culture and eventual decellularization of the cell tube to leave behind ECM
[95]. This ECM can then be seeded with autologous cells prior to implantation. Although
successful in early clinical trials, this technique is both costly and time consuming.
Additionally, cells may be seeded into a custom mold to promote cell fusion and
assembly of cellular aggregates. While these tissues can be assembled rapidly and with
controlled geometry and composition, difficulties often arise with low mechanical
properties and tissue necrosis [103]. Finally, tissues can be printed using custom inkjet
printers or bioink & biopaper combinations [132, 134]. While such strategies offer rapid
fabrication times and precise control of vessel geometry and composition, they are in the
developmental stage, often requiring maturation prior to use and encountering difficulty
matching required mechanical properties.
1.4. Nanotechnology in Tissue Engineering
The use of nanotechnology for applications in tissue engineering has been utilized
due to the integrative methods with which nanomaterials can be applied to tissue
engineering [135-139]. The main goals of incorporating nanotechnology with tissue
engineering entail mimicking nanostructures of the native tissue and to integrate
functionalities that conventional tissue engineering cannot address [110]. Typical
methods to integrate nanotechnology into tissue engineering involve nanolithography,
nanowires, nanofibers, nanoparticles, surface coating, and drug delivery (Figure 1.4)
[140]. Nanolithography allows for the control of physical surface properties at the
nanometer level. This is useful in vascular tissue engineering as it can modify the surface
of a graft to closely mimic the native extracellular matrix, as the ECM has been shown to
regulate cellular functions such as morphogenessis, differentiation, proliferation,
adhesion, and migration [141].

Studies have shown that surface patterning and

topography are important in cell adhesion and differentiation, with materials possessing
nanopatterned surfaces demonstrating improved cell adhesion and function (endothelial,
smooth muscle) compared to unpatterned materials [142-144].

24

Additionally,

investigations into a variety of materials (collagen, elastin and polymers such as PLLA,
PLGA, and PCL) have been undertaken to determine their suitability as nanofibers for
scaffold materials in vascular tissue engineering. Indeed, electrospun nanofiber scaffolds
composed of 45% (by weight) collagen, 15% elastin, and 40% biodegradable polymer
have already been fabricated that mimic the native ratio of collagen and elastin in blood
vessels [92].

Nontoxic scaffolds, with fibers 477-765 nm in diameter, exhibited

significant cell infiltration throughout the scaffold after 21 days in culture. Electorspun
small diameter vascular grafts have demonstrated high long-term patency rates in vivo
with noticeable tissue integration and scaffold degradation over time [145, 146].
Nanotechnology has also been applied to vascular grafts to locally deliver bioactive
factors including growth factors, drugs, antibodies, and genes [147-149].

Overall,

nanotechnology is applicable to vascular tissue engineering in a variety of methods to
improve tissue integration and functionality. Though in vivo results have been promising,
further investigation is necessary to fully elucidate these nano-scale interactions [94, 110,
150, 151].
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Figure 1.4. Applications for Nanotechnology in Tissue Engineering. Nanotechnology
has been the subject of recent research for integration into tissue engineering constructs
due to its ability to mimic the native ECM and cellular environment. Strategies
employed include nanolithography, nanowires, nanofibers, nanoparticles, surface coating,
and drug delivery across a variety of tissue engineering fields [140]. Nanolithography
has been applied to modify the surface geometry of tissue scaffolds to promote, deter, or
control cell and protein interactions [142, 144]. Nanofibers can be used to closely mimic
the small scale of ECM fibers throughout the cell and its native environment, thereby
closely mimicking the surrounding environment and promoting cell integration [145,
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146]. Additionally, chemical modifications can be made to the scaffold to either coat the
surface to control biological interactions, or to load scaffolds with drugs or growth factors
to promote integration [148, 149].
1.5. Magnetic Nanoparticles in Tissue Engineering
Magnetic nanoparticles (MNPs) have gained interest in biomedical applications
due to their complementary and multifunctional capabilities in imaging, drug delivery,
and magnetic targeting, with some iron oxide MNP formulations currently FDA approved
and serving as treatments for iron deficiency (Feraheme) or MRI contrast agents
(Feridex) [152-154].

MNPs can be modified to allow researchers to control MNP

interaction within the body at sub-cellular levels. Furthermore, MNPs can serve multiple
simultaneous functions (i.e. imaging agent and targeted drug delivery), allowing for more
effective treatment modalities. Currently, MNPs have been investigated for applications
in magnetic hyperthermia for cancer therapy [155, 156], magnetic cell separation for
diagnostics [157, 158], in vivo cell tracking for imaging [159, 160], and even in vivo
monitoring of transplanted tissues [161, 162]. However, the prolonged presence of MNPs
can have adverse effects on cells, such as cell toxicity, changes in cell phenotype, or
changes in cell mobility [163-165]. Surface functionalization or coating of MNPs in
materials such as oleates [166, 167], dextran [154, 168], or polymers [162, 169] can
enhance MNP biocompatibility and functionality by improving cell viability, uptake, or
biodistribution.

These techniques often involve complex chemistry and do not

necessarily accelerate the removal of MNPs from the body. Therefore, methods to alter
MNPs so their presence in the body is limited will benefit biomedical MNPs. Ideal
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biomedical MNPs would remain stable for sufficient time to accomplish their desired role
and rapidly degrade once their task is completed.
Iron oxide MNPs are ideal for tissue engineering applications due to their
superparamagnetic properties and ability to fabricate uniform particle sizes that can be
functionalized to suit desired requirements. However, a primary concern with biomedical
MNPs is their fate within the body. Following systemic administration, larger iron oxide
MNPs (>200 nm diameter) are sequestered by the spleen as a result of mechanical
filtration [170].

These MNPs are ultimately removed from the cells through

phagocytosis, while MNPs with small diameters (<10 nm) are rapidly cleared thought
extravasations and renal clearance. Iron oxide MNPs, once internalized into cells, are
directed to lysosomes where the low pH and enzymatic activity metabolize the
nanoparticle into iron and oxygen [171, 172]. Intercellular enzymes work to catalyze the
oxidation of Fe(II) to Fe(III), which can be bound to transferrin, an iron binding
glycoprotein that regulates the level of free iron in biological fluids and tissues [173].
The biodistribution and pharmacokinetics of MNPs are also a concern in biomedical
applications. Following intravenous injection, Jain et al. showed that MNPs primarily
localized in the liver and spleen, but MNPs were also found in the brain, heart, kidneys,
and lungs [174]. Roughly 55% of the injected iron was localized in the liver 6 hours after
injection, with 50% and 25% of the injected iron still present in the liver and spleen after
3 weeks, respectively. Furthermore, their results also confirm that the injected iron oxide
does degrade over time, with magnetization measurements of the liver and spleen
showing a steady decrease over 3 weeks.
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Studies have confirmed that portions of

injected MNPs are excreted through urine and feces, with some formulations showing as
much as 35% after 28 days [175] while others demonstrate 18-22% excretion after 7
weeks [176]. However, methods that can accelerate this MNP degradation will limit the
interaction of MNPs with the biological environment, which is expected to be critical to
reduce cytotoxicity.
A variety of different chemicals have been investigated to accelerate the
degradation of iron oxide MNPs. The ability to increase the degradation rate of MNPs
within the body will allow for decreased exposure of cells and the body to these MNPs,
and thereby limit their interaction. Multiple acids have been confirmed to dissociate iron
oxide, including oxalic, citric, lactic, and acetic acids [177]. Miller et al. confirmed that
of thirteen acids tested, oxalic and citric acid (0.1 M) lead to complete dissociation of
iron oxide over 100 hours at pH 3.5 at room temperature, with less complete dissociation
occurring at pH 5.5 compared to pH 3.5. Lactic acid also led to dissociation of iron
oxide, demonstrating roughly 80% degradation at pH 3.5, but only 10% degradation at
pH 5.5. However, other studies have shown that exposure of cells to pH 5.7 or below
using acetic and lactic acid (0.12-0.16 M) induced toxicity on cells [178]. These results
highlight that while acids can be used to induce degradation of iron oxides, the acidic
environment required for iron oxide degradation can be detrimental to cells.
While it is clear that incubation in an acidic environment leads to accelerated
degradation of iron oxide, a method to control this acidic environment such that its
effects on cells are limited is needed for biomedical applications.

Polymeric

microparticles and nanoparticles can be utilized to create localized acidic environments
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due to their degradation, which creates a local acidic microenvironment generated from
degradation byproducts including lactic and glycolic acid. Studies have confirmed that
degradation of PLGA(50/50) microparticles creates a spatial acidic environment within
degrading particles over the course of 15 days [179]. Microspheres formed using a
double emulsion technique revealed a pH of 1.5 within the core of microparticles, but
maintained a pH greater than 3.5 on the edge of particles.

Utilization of low

concentrations of polymeric particles will not effect the overall pH of the
macroenvironment due to a localized decrease in pH in the particle microenvironment.
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CHAPTER 2
JANUS MAGNETIC CELLULAR SPHEROIDS
2.1. Introduction
Three dimensional cell cultures, or spheroids, have been investigated as tissue
engineered building blocks due to their ability to mimic the native cellular and
extracellular matrix (ECM) environment. Methods to pattern cellular spheroids include
direct seeding into a mold [1, 2], printing into hydrogel or biopaper [3-5], or surface
patterning to promote adhesion [6-9]. Nanotechnology has emerged as pivotal part of
biomedical engineering practices, with successful applications in imaging [10, 11], drug
delivery [12, 13], biosensors [14, 15], and tissue engineering [8, 16-19]. By tailoring and
controlling interaction at a sub-cellular level, nanotechnology can be used to improve
biocompatibility, tissue integration, and assembly of complex tissues or scaffolds [9, 20,
21]. The use of magnetic forces to manipulate and align cells or cellular spheroids can be
utilized for this patterning and expanded into tissue engineering [22-28]. A variety of
methods that utilize internalization of MNPs into cells have been investigated to integrate
MNPs with tissue engineering, including MNP conjugation/binding to the cell [24, 28,
29], cellular internalization [30-33], and mixing MNPs within the ECM [22, 30, 34].
These methods typically produce adverse effects related to MNP uptake into cells,
however, highlighting the need to limit MNP and cell interaction. In the presented
approach, we go beyond current MNP approaches by reducing MNP interactions with
cells, thereby avoiding adverse effects [22, 23, 29, 33, 35], while still allowing for
magnetic manipulation. These novel structures possess two segregated domains, one
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composed of cells and the other of extracellular MNPs to form a Janus magnetic cellular
spheroid (JMCS, Figure 2.1). The ability to magnetically assemble engineered building
blocks that maintain long-term cell viability and stable phenotype is critical for
incorporating MNPs into tissue structures. To our knowledge, this is the first report of
JMCS structure as building blocks for tissue engineering.
Dispersed

Uptake

Cell

MNP

Janus

ECM

Figure 2.1. Methods to Incorporate MNPs into Cellular Spheroids. Janus magnetic
spheroid structures do not exhibit the cytotoxic affects associated with MNP
internalization common to dispersed and uptake methods by separating MNPs and cells
into segregated and distinct regions. The combination of MNPs (black), cells (pink), and
ECM (collagen, blue) into segregated regions decreases cellular toxicity related to MNPs
by decreasing interactions with cells.
2.2 Materials & Methods
An overview of experimental procedures, parameters, and objectives can be found
in Table 2.1.
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Experiment

Parameters

Uptake vs. Janus

Spatial Location of MNPs
within Cellular Spheroids

Objective

•Determine effect of MNP interaction
•Method to incorporate
on cell viability and function
MNPs into magnetic
cellular spheroids
•MNP Internalization
•Viability
•Tissue Patterning
*All samples analyzed on Day 3
•Analyze segregation of MNPs and
cells using Janus technique to
incorporate MNPs

•MNP Content
•Janus

*All samples analyzed on Day 3
Spheroid Viability

•JMCS Composition
•Collagen*
•Elastin*
•Cell Number*
•MNP Content*
•Long Term**

•Determine effect of JMCS composition
on cell viability using qualitative and
quantitative methods
*Samples analyzed on Day 3
**Samples analyzed on Day 3, 1 WK,
3 WK, 5 WK, 7 WK

Phenotype Expression

•Spheroid Type
•Janus
•Uptake
•No MNP

•Determine effect of MNP interaction
on SMC phenotype expression using
qualitative and quantitative techniques

YY

Y
Y

YY

Y
Y

Collagen Synthesis

*All samples analyzed on Day 3
•Determine effect of MNPs on collagen
synthesis within cellular spheroids

•Time

Time
*Samples analyzed on Day 3, 10, 20,
30, 40

Cell

Y Antibody

MNP

Ring Magnet

ECM

Glass Coverslide

Table 2.1. Experimental Plan for Janus Magnetic Cellular Spheroid Analysis.
Experiments were performed to compare JMCSs to common Uptake magnetic cellular
spheroids, histologically analyze the segregation of MNPs and cells within JMCSs,
determine factors affecting JMCS viability, determine the effect of MNPs on SMC
phenotype expression within JMCSs, and determine the effect of MNPs on collagen
synthesis within JMCSs. Multiple parameters were varied within each experiment as
noted.
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2.2.1. Statistical Analysis
All statistical analysis was performed using a two-tailed t-test with at least three
repeats each. Statistical significance was set at p < 0.05. Error bars on graphs represent
the standard deviation from the mean.
2.2.2. Cell Culture
Primary rat aortic smooth muscle cells (SMCs), primary rat aortic fibroblasts
(FBs), and human adipose-derived stem cells (ADCSs, Lonza) were used for all studies.
All cells were cultured in monolayer cultures at 37 °C and 5% of CO2 until spheroid
assembly. SMCs were cultured using Dulbeco’s Modified Eagle Medium:F-12 (ATCC,
1:1, DMEM:F-12) supplemented with 10% fetal bovine serum (Atlanta Biologics) and
1% penicillin-streptomycin-amphotericin (MediaTech, Inc.). FBs were cultured using
Dulbeco’s Modified Eagle Medium supplemented with 10% fetal bovine serum and 1%
penicillin-streptomycin-amphotericin.

ADSCs were cultured using adiposed-dervied

stem cell basal medium (Lonza) supplemented with 10% fetal bovine serum, 1% Lglutamine (Lonza), and 0.1% gentamicin-amphotericin B (GA-1000, Lonza).
2.2.3. Spheroid Assembly
To assemble JMCSs, iron oxide MNPs (Fe3O4, 20 – 30 nm, SkySpring
Nanomaterials, Inc.), collagen (Bovine, Type I, Life Technologies), and cells in cell
culture media were dispensed using a modified hanging drop method into 15 µL droplets
[24]. Samples were inverted and incubated at 37 °C with 5% CO2 for three days prior to
use to allow for spheroid assembly. Specific details on the modified method cannot be
disclosed at this time. Unless otherwise noted, all spheroids were assembled using SMCs
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with MNPs, 20,000 cells per spheroid, and collagen.

To assemble uptake MNP

spheroids, a monolayer cell culture flask (~90% confluence) was incubated with MNPcontaining cell culture media (300 µg/mL) for 24 hours. The bottom of culture flasks
was covered with square magnets (K&J Magnetics, Inc., 12.7 x 12.7 mm, 1.6 mm thick,
vendor calculated pull force = 3.59 lbs) to promote MNP internalization into cells. Media
solutions containing MNPs were sonicated prior to addition to cells. After incubation,
cells were washed 5x to remove free MNPs, trypsinized (0.25%, Thermo Scientific),
collected, and placed on a magnetic wash tool and allowed to sit for 5 minutes. The
supernatant was discarded and remaining magnetically attracted cells suspended in fresh
media.

Solutions of magnetically attracted cells and collagen were combined and

dispensed using a hanging drop method as mentioned previously. Collagen was prepared
according to manufacturer recommendations and kept on ice prior to use for all samples.
MNPs were washed three times with a magnetic wash tool prior to use to remove
byproducts.
2.2.4. Histology
JMCSs were processed and sectioned via standard paraffin sectioning techniques.
Briefly, spheroids were fixed with Z-Fix (buffered zinc formalin, Anatech Ltd.) and
dehydrated using ethanol and xylene prior to paraffin embedding. 5 µm thick sections
were stained using hemotoxylin and eosin (H&E) and Masson’s Trichrome (Poly
Scientific). JMCSs were collected and analyzed after three days of assembly in hanging
drop.
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2.2.5. Viability
PrestoBlue (Life Technologies) and MTT (Sigma) cell viability assays were
performed to quantify cell viability (at least 3 repeats per sample). Spheroids were
dissociated via incubation with collagenase (Collagenase Type IV, Life Technologies).
Spheroids were centrifuged and physically dissociated, then allowed to adhere overnight
on a well plate. Viability was also qualitatively analyzed following manufacturer’s
specifications (Life Technologies) using simultaneous live / dead fluorescent staining and
imaging using Calcein, AM (live) and ethidium homodimer-1 (EthD-1, dead). Spheroids
were stained, fixed using Z-fix, and imaged using a Nikon Eclipse Ti confocal
microscope. All JMCSs were collected and analyzed after three days of assembly in
hanging drop except those used for long-term viability studies. Spheroids used for long
term viability studies were cultured in non-treated well plates with media changes every
other day.
2.2.6. Quantification of MNP Internalization
First, cellular spheroids (25, Janus and Uptake) were dissociated. Dissociated
samples were suspended in 1 mL fresh media and placed on a magnetic wash tool for five
minutes. The supernatant was collected, and the remaining cells (magnetically attracted)
suspended in 1 mL fresh media. The amounts of cells in the supernatant and magnet
solution were quantified using a hemocytometer. Spheroids were collected and analyzed
after three days of assembly in hanging drop.
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2.2.7. Phenotype Analysis
Flow cytometric analyses were conducted using a Beckman Coulter Astrios cell
sorter. Spheroids were dissociated, filtered, suspended in CytoFix/Cytoperm buffer, and
incubated with primary antibodies for 30 minutes at 4 °C. Three SMC markers were
analyzed: smooth muscle !-actin (SMAA) conjugated with Cy3 (Sigma-Aldrich), smooth
muscle 22 (SM22, Abcam), and smooth muscle myosin heavy chain (SMHC, Biomedical
Technologies, Inc.). Antibodies used include: SMAA – mouse monoclonal anti-actin, !smooth muscle – Cy3 antibody, SM22 – rabbit polyclonal anti-SM22 alpha antibody,
SMHC – rabbit anti-smooth muscle myosin IgG antibody. Samples were washed 3x with
Cytowash buffer and incubated with secondary antibodies for 30 minutes at 4 °C. Next,
samples were washed once with Cytowash buffer, followed by one wash in FACs buffer
(1% bovine serum albumin in PBS). Samples were resuspended in FACs buffer and
analyzed via flow cytometry. Rabbit IgG-Cy5 (Jackson ImmunoResearch) was used as a
secondary antibody.
Immunofluorescence microscopy was used to qualitatively confirm SMC
phenotype expression within samples. First, OCT embedded histology sections (5 µm
thick) were collected and cleared via two washes (5 minutes) in PBS and 1 wash in water.
Samples were circled with a diamond tip pen. Samples were treated with a 0.1% Triton
X-100 to permeabilize samples (10 minutes). Slides were washed 3x with water (5
minutes), followed by a 30 minute incubation with Background Buster (Innovex
Biosciences). Next, samples were washed 2x water and 1x PBS. Once samples were
prepped, they were incubated with primary antibodies overnight at 4 °C in a humid

53!

chamber.

Samples were washed 3x PBS, followed by incubation with secondary

antibodies for one hour at room temperature. As a control, samples were incubated with
just the secondary antibody to ensure controlled binding was occurring. Finally, samples
were washed 3x PBS followed by incubation with Hoechst 33342 to stain for nuclei (10
minutes, room temperature). Samples were washed 3x PBS and cover slipped, and
fluorescently imaged for SMHC and SM22 (FITC, Ex/Em 492/520), SMAA (Cy3,
Ex/Em 552/570), and nuclei (Hoescht 33342, Ex/Em 343/483). Results were analyzed
and compared to samples containing no MNPs to determine the effects of MNP
integration on SMC phenotype marker expression. Three samples of each formulation
were analyzed to confirm that results were consistent. Spheroids were collected and
analyzed after three days of assembly in hanging drop.

2.3. Results & Discussion
2.3.1. Janus vs. Uptake Magnetic Cellular Spheroids
To analyze the spatial localization of MNPs and cells within JMCSs, samples
with Janus structures were histologically sectioned and stained using Masson’s
Trichrome (Figure 2.2A) and hemotoxylin and eosin (H&E, Figure 2.2 B-E). Samples
containing MNPs showed localization of MNPs and cells into distinct regions. Overall,
the concept of using magnetic forces to manipulate cellular spheroids has been shown to
be promising, but the advances to integrate MNPs with tissue fabrication have failed due
to toxicity related to MNP uptake into cells or adverse affects on cell function and
morphology [33, 36, 37]. Ultimately, a magnetic cellular spheroid structure possessing
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two segregated domains, one composed of cells and one composed of MNPs, will fully
incorporate the positive benefits of using magnetic cellular spheroids to go beyond
current approaches. The formation of separate domains reduces the interaction and
uptake of MNPs into cells, thereby avoiding any adverse effects while still allowing for
magnetic force manipulation.
A
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B
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Figure 2.2. Structure of Janus Magnetic Cellular Spheroids. (A) The separation of
MNPs and cells is present within JMCSs containing dispersed collagen and cells with a
segregated MNP domain (Masson’s Trichrome) (B-E) Samples were stained using H&E
to confirm the presence and segregation of MNPs within cellular spheroids, (No MNPs =
B, increasing MNP concentrations C-E, scale bars = 100 µm). Results confirm the
segregation of MNPs (black) and cells (purple) into distinct domains using multiple MNP
concentrations.
Next, JMCSs were compared to Uptake MNP spheroids to determine if the Janus
structure improved upon MNP interaction with cells within cellular spheroids. The
amount of cells that internalized MNPs were quantified and showed that JMCSs resulted
in significantly lower internalization (35%) compared to uptake spheroids (83%, p <
0.05, Figure 2.3A). Next, cellular viability using both Janus and Uptake cellular
spheroids was analyzed up to one week to determine their capacity for tissue engineering
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applications which involve prolonged interaction between MNPs and cells. A viability
analysis (300 µg/mL MNP) also showed that JMCSs maintained high viability
comparable to control spheroids without MNPs, while uptake spheroids resulted in lower
viability at Days 3 and 7 (p < 0.05, Figure 2.3B). Finally, the use of JMCSs was
compared to conventional uptake magnetic cellular spheroids for tissue assembly (Figure
2.3C). Spheroids were assembled onto a magnetic pattern and allowed to fuse for 48
hours, at which point the magnet was removed (Figure 2.3C, before), and the rings were
transferred to new a chamber. Fused rings composed of Janus spheroids maintained
tissue structure in contrast to those composed of uptake spheroids, which dissociated
upon handling (Figure 2.3C, after). Based off viability results, this dissociation is due to
decreased cell viability, and therefore tissue integrity, of Uptake magnetic cellular
spheroids. Results confirm that the method used to incorporate MNPs into cellular
spheroids is critical, as internalization of MNPs clearly has an effect on cell viability.
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Figure 2.3. Janus vs. Uptake Magnetic Cellular Spheroids. (A) The amount of cells
per spheroid that internalized MNPs was quantified and revealed that JMCSs (35%)
resulted in significantly less MNP internalization than uptake cellular spheroids (83%, *
p < 0.05). (B) Additionally, cell viability analysis of cellular spheroids fabricated using
Janus and uptake methods revealed that JMCSs maintained high viability compared to
control spheroids without MNPs, while uptake spheroids exhibit low viability (* p <
0.05) at Days 3 and 7. (C) The use of both spheroid types for tissue engineering
applications was analyzed by assembling fused rings via magnetic patterning. After 48
hrs of fusion, the magnetic patterns were removed and the rings transferred to another
chamber. Results revealed that rings assembled using uptake spheroids unable to be
physically manipulated and broke apart upon handling. Rings assembled using Janus
spheroids, however, were capable of handling, and therefore applicable to tissue
engineering applications (scale bars = 1000 µm).
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2.3.2. Factors Affecting Cell Viability
To determine the capacity for JMCSs to be utilized across a variety of tissue
engineering applications, quantitative and qualitative methods were used to analyze
viability using various JMCS formulations. Cell density, ECM content and ECM
composition have been demonstrated to be critical to tissue formation and fabrication [4,
38, 39]. First, the effect of JMCS composition on cell viability was analyzed by varying
the length of culture (Figure 2.4 A,B) and on different cell types (Figure 2.5A). Next,
using rat aortic smooth muscle cells (SMCs) and rat aortic fibroblasts (FBs), the effect of
JMCS composition on spheroid viability was analyzed.

JMCSs were fabricated to

determine the effects of various collagen I and elastin contents (Figure 2.5 B,C),
collagen I and elastin ratios (Figure 2.5D), and cell densities (Figure 2.5E) on spheroid
cellular viability. For all formulations, the MNP concentration was held constant at 0.3
mg/mL. Cell viability was quantified up to seven weeks, with results demonstrating
sustained high viability over the seven weeks compared to cellular spheroids without
MNPs (Figure 2.4 A,B). Statistical analysis on long-term viability samples showed
significant differences between samples at Day 3 and 1 Week, but in favor of JMCSs
compared to controls (normalized viability greater than 100%). Though a statistically
significant difference was noted at 5 Week (p < 0.05), this difference disappeared at
Week 7. Spheroid viability was also qualitatively assessed at 7 weeks using simultaneous
live/dead staining, confirming equivalent expression in spheroids with and without MNPs
(Figure 2.4B). These results confirm the long-term in vitro viability of JMCSs. Second,
we prepared JMCSs using three different cell types to determine if cell viability was
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dependent on cell type (Figure 2.5A), which could prevent further applications to
fabricate multicellular tissues. Compared to samples without MNPs, JMCSs composed of
rat aortic smooth muscle cells, human adipose derived stem cells (ADSCs), and rat aortic
fibroblasts maintained high cell viability. Next, the effect of JMCS composition on
viability was analyzed up to one week using SMCs and FBs. Results showed that
collagen I concentrations ranging from 0.01 mg/mL to 1.3 mg/mL had no adverse effects
on cell viability when compared to spheroids without collagen I (Figure 2.5B).
Additionally, elastin concentrations ranging from 0.005 mg/mL up to 0.65 mg/mL
maintained high viability when compared to control spheroids without elastin (Figure
2.5C). Next, holding the total ECM content constant (0.24 mg/mL), elastin to collagen
ratios were varied to mimic variations in ECM between different tissue types. Results
showed that various elastin to collagen ratios from 0.3 to 1.5 had no adverse effects on
spheroid viability when compared to spheroids without ECM (Figure 2.5D). Finally, the
density of cells within JMCSs was varied, ranging from 20,000 to 100,000 cells per
spheroid. High viability was maintained at all cell densities when compared to spheroids
without iron oxide MNPs (Figure 2.5E). High viability was maintained for both cell
types tested, SMCs and FBs, for all JMCS formulations. Viability was also maintained in
short term studies with MNP concentrations up to 5 mg/mL (Figure 2.6), demonstrating
a decreased cytotoxicity compared to previous studies [23, 32, 33, 36, 37] primarily due
to the nature of the JMCS’s segregated domains. Additionally, the ability of JMCSs to
maintain high viability across a variety of ECM and cellular compositions makes them
appealing for tissue engineering applications due to their capacity to be used for the
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assembly of various tissue types. Additionally, groups have shown that cell density is
critical to fabricating tissue constructs, as higher cell density spheroids have lead to
increased viability and metabolic output, compared to lower cell densities [40].

This

novel method for MNP-incorporation is expected to overcome the problems associated
with MNP internalization, thereby allowing for more complex and long-term applications
using MNPs in tissue engineered constructs. The ability to magnetically assemble tailored
engineered building blocks with controlled cell and ECM compositions provides a
capability to assemble tissue structures with tailored compositions.
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Figure 2.4. JMCS Viability – Long Term. (A,B) Results demonstrated that using Janus
magnetic cellular spheroids structures, long term viability was maintained up to 7 weeks,
confirmed both qualitatively (confocal microscopy, live/dead stain) and quantitatively
compared to spheroids without MNPs (scale bars = 500 µm). Statistical analysis showed
significant differences between Janus MNP and control cellular spheroids without MNPs
at day 3, 1 week, and 5 week (* p < 0.05).
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Figure 2.5. JMCS Viability – Varying Cellular and ECM Compositions. (A)
Viability of JMCSs was not affected by cell type used, with high viability maintained
using human adipose-derived stem cells (ADSCs), rat arotic fibroblasts (FBs), and rat
aortic smooth muscle cells (SMCs). Furthermore, results demonstrate high viability of
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(B) varying collagen, (C) varying elastin, (D) varying elastin:collagen ratios, and (E)
varying cell number in JMSCs up to one week. High viability was maintained using both
smooth muscle cells (SMCs) and fibroblasts (FBs) for collagen concentrations up to 1.3
mg/mL, elastin concentrations up to 0.65 mg/mL, varying elastin/collagen ratios, and at
various cell densities. Spheroids were compared to control spheroids without the
respective ECM component (collagen, elastin) or iron oxide MNPs (varying cell
number). When varying collagen and elastin content, some samples from both cell lines
demonstrated statistically significant differences compared to controls with no ECM (* p
< 0.05), but all samples maintained greater than 90% viability and were therefore
considered to maintain high viability. Additionally, when varying cell number, some
samples demonstrated significant differences compared to control samples without
MNPs. However, all samples maintained greater than 90% viability, and were therefore
considered to maintain high viability.
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Figure 2.6. Effect of Varying MNP Concentrations on JMCS Viability. Viability
analysis confirmed no statistically significant differences in viability at Day 3 when
comparing spheroids with varying MNP concentrations to those without MNPs (t-test, p
> 0.05, three repeats each).
2.3.3. Factors Affecting Cell Phenotype
Once viability was confirmed, we analyzed samples to determine any adverse
effects of MNPs on cell phenotype expression. Flow cytometric analysis was performed
on cells from spheroids (control with no MNPs, Janus MNPs, and Uptake MNPs) to
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determine the percentage expression of three SMC markers: smooth muscle !-actin
(SMAA), smooth muscle 22 (SM22), and smooth muscle myosin heavy chain (SMHC,
Figure 2.7A). Compared to no MNP control spheroids, JMCSs, and Uptake MNP
spheroids maintained equivalent expression of SMAA (99% and 93% respectively,
normalized to control). Additionally, high SM22 expression was maintained for Janus
spheroids (95%), while Uptake spheroids resulted in decreased expression (74%).
However, the addition of MNPs using the Janus method did result in a slight decrease in
SMHC expression compared to no MNP controls (75%), while Uptake MNP spheroids
exhibited a significant decrease in expression (16%). These results were also qualitatively
analyzed using immunofluorescence microscopy (Figure 2.7B), with a uniform
dispersion of markers throughout JMCSs compared to controls without MNPs. These
results indicate that the presence of MNPs within Janus spheroids did not affect cell
phenotype, compared to spheroids without MNPs as both populations expressed SMCspecific markers at similar levels. Although some studies have shown that MNPs have
no adverse effects on cell phenotype [34, 41], others have demonstrated adverse impact
on cell motility, length, and other morphological abnormalities, suggesting that use of
MNPs results in altered cell phenotype [36, 37]. Consequently, it is critical to prevent
MNP interactions with cells for tissue engineering applications.
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Figure 2.7. Effect of MNPs on Cellular Phenotype. (A) SMC phenotype expression of
three known SMC markers was quantified using flow cytometry (at least 1 million cells
analyzed per sample). Results indicate that JMCSs exhibited similar expression of all
three markers compared to controls, while uptake MNP spheroids results in decreased
expression of SM22 and SMHC. (B) Phenotype expression was qualitatively confirmed
using IHC microscopy (red and green = marker, blue = nucleus), confirming uniform
dispersion and equivalent expression levels of SMC phenotype markers in JMCSs
compared to control spheroids without MNPs.
2.3.4. JMCSs for Tissue Engineering – Collagen Synthesis
Collagen occupies the extracellular space and regulates cellular activity and tissue
function by providing a natural scaffold for controlling the spatial arrangement of cells
within tissues [42, 43]. An appealing aspect of cellular spheroids for tissue engineering
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applications is their ability to dynamically produce their own ECM to meet required
mechanical or functional needs of the local environment [2]. Therefore, experiments
were performed to provide evidence of this phenomenon and to confirm that using
JMCSs, the addition of iron oxide MNPs has no adverse effects on collagen synthesis.
First, we demonstrated that JMCSs could be tailored to contain controlled ECM contents,
as confirmed using collagen for a proof of concept (Figure 2.8A). Using Masson’s
Trichrome stain to visualize collagen, these results demonstrated that collagen content
can be tailored in the fabrication process. Next, spheroids were histologically sectioned
and stained to visualize collagen production up to Day 40 (Figure 2.8B). Initial collagen
concentrations were held constant at 0.017 mg/mL for spheroids with and without MNPs.
Results demonstrated that JMSCs and MNP-free spheroids secrete their own collagen, as
confirmed by an increase in collagen within cellular spheroids over time. Furthermore,
visual analysis suggested that the addition of MNPs to cellular spheroids lead to
increased collagen production compared to MNP-free spheroids. These results suggest
that the presence of MNPs within cellular spheroids has no adverse effects on collagen
synthesis, and that MNPs may stimulate accelerated collagen synthesis compared to
MNP-free controls. Therefore, JMCSs are a viable candidate for tissue engineering
applications due to their ability to secrete their own ECM as the engineered tissue
develops. Collagen and elastin are the two most important matrix proteins that mediate
the mechanical properties of tissues [38, 43]. Thus, the development of a viable tissue
engineered construct with mechanical properties similar to native tissues heavily relies on
enhancing collagen and elastin production.
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Figure 2.8. Effect of MNPs on Collagen Synthesis within JMCSs. (A) Collagen
content can be controlled in the fabrication process, confirmed using Masson’s Trichrome
stain. Visual analysis confirms an increase in collagen (blue) content as the initial
collagen content is increased during the JMCS fabrication process. (B) JMCS and MNPfree spheroids both secrete their own collagen over time, confirming that MNPs have no
adverse effects on collagen synthesis within cellular spheroids. Using Masson’s
Trichrome, this was visually confirmed by the increase in collagen (blue) over time up to
Day 40. Scale bar = 500 µm.
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2.4. Conclusions
Results indicate that while MNPs can be incorporated into cellular spheroids
using a variety of different techniques, they can induce adverse effects on cells.
However, the method in which MNPs are incorporated into cellular spheroids is critical,
as Janus structures reduce adverse effects seen in Uptake MNP cellular spheroids.
Cytotoxicity and phenotypic analyses showed that the JMCS structure can integrate
MNPs with biological structures without compromise to cells, thus extending beyond
current approaches using MNPs to engineer heterogeneous constructs composed of
multiple cell lines. Due to the requirement of long-term cell and MNP interactions to
prepare fully functional complex tissues, it is critical to maintain long-term cell viability
and phenotype. Furthermore, JMCSs have no adverse effects on collagen synthesis
within cellular spheroids, making them ideal candidates for tissue engineering
applications due to the mechanical support provided by collagen.
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CHAPTER 3
SPHEROID FUSION USING MAGNETIC FORCE ASSEMBLY
3.1. Introduction
Scaffold-free cellular aggregates produce and secrete their own extracellular
matrix (ECM) and can fuse into complex tissue structures [1-4]. Fabrication of functional
tissue engineered constructs with appropriate cell densities, ECM contents, and
mechanical properties that mimic native tissues still remain a challenge due to the lack of
understanding associated with tissue fusion and maturation mechanisms [3, 5]. A critical
process in the fabrication of complex tissue structures with cellular spheroids is related to
their fusion [4]. Tissue fusion is a self-assembly process in which two or more distinct
cell populations, or tissues, make contact and coalesce to form a single cohesive structure
[2-4]. Though the process is not clearly understood, research has shown that factors
mediating tissue fusion include cell migration, cell-cell interactions, and cell-matrix
interactions [2, 4, 6]. Tissue fusion is driven by minimizing the overall system
configurational energy, which results in smaller tissue aggregates [2, 7].
By incorporating magnetic nanoparticles (MNPs) into cellular spheroids, tissues
can be aligned and patterned using magnetic force assembly [8-14]. Furthermore,
magnetic forces can mediate and enhance tissue fusion by promoting cell-to-cell contacts
and interactions. These increased interactions arise from the adhesive and cohesive
interactions between cells under the influence of magnetic attraction. Conventional nonmagnetic tissue assembly and fabrication methods include cell printing, cell sheet
techniques, and patterned molds [2, 3, 15, 16]. These non-magnetic methods spatially
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orient the cells into a desired position through passive contact, but do not address active
contact mediated by forces. Therefore, Janus magnetic cellular spheroids (JMCSs) were
used as a model for spheroid fusion mediated by magnetic forces. Results demonstrated
that magnetic forces play a large role in mediating spheroid fusion when using magnetic
force assembly. An understanding of the role of MNPs and magnetic force in mediating
spheroid fusion can lead to optimization of tissue patterning and printing to promote
fusion in a desired direction.

3.2. Materials & Methods
An overview of experimental procedures, parameters, and objectives can be found
in Table 3.1.
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Experiment
Magnetic Force Assembly

Parameters
•Magnetic Pattern
•Shape
•Size

Objective
•Determine capacity of JMCSs to
assemble and fuse into homogenous
tissues using magnetic force assembly
*Samples analyzed Day 4 fusion!

Factors Affecting Fusion

•Magnetic Forces
•Magnetic Field
Force
•JMCS Spheroid
MNP Content

•Determine factors mediating assembly
and fusion of JMCS using magnetic
force assembly

*Samples analyzed daily up to 1 WK
Assemble Complex Tissue •Time*
•Cell Type and
Spatial Location**
•Unilayer
•Bilayer
•Trilayer

•Determine capacity of JMCSs to
assemble and fuse into a complex
vascular tissue construct

*Samples analyzed Day 4 and Day 10
fusion
**Samples analyzed Day 10 fusion

Janus Magnetic Cellular Spheroid (JMCS)
Ring Magnet
Glass Coverslide

Table 3.1. Experimental Plan for Analysis of JMCS Fusion into Complex Tissues.
Experiments were performed to analyze the ability to assemble fused tissues using
JMCSs and magnetic force assembly. Furthermore, studies were performed to determine
factors mediating JMCS fusion into complex tissues, and the capacity of JMCSs to be
used for the assembly of a complex multicellular vascular tissue construct. Multiple
parameters were varied within each experiment as noted.
3.2.1. Statistical Analysis
All statistical analysis was performed using a two-tailed t-test with at least three
repeats each. Statistical significance was set at p < 0.05. Error bars on graphs represent
the standard deviation from the mean.
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3.2.2. Cell Culture
Primary rat aortic smooth muscle cells (SMCs), primary rat aortic fibroblasts
(FBs), and rat aortic endothelial cells (ECs, Cell Applications, Inc.) were used for all
studies. All cells were cultured in monolayer cultures at 37 °C and 5% of CO2 until
spheroid assembly. SMCs were cultured using Dulbeco’s Modified Eagle Medium:F-12
(ATCC, 1:1, DMEM:F-12) supplemented with 10% fetal bovine serum (Atlanta
Biologics) and 1% penicillin-streptomycin-amphotericin (MediaTech, Inc.). FBs were
cultured using Dulbeco’s Modified Eagle Medium supplemented with 10% fetal bovine
serum and 1% penicillin-streptomycin-amphotericin.

ECs were cultured using Rat

Endothelial Cell Growth Medium (Cell Applications, Inc.).
3.2.3. Spheroid Assembly
To assemble JMCSs, iron oxide MNPs (Fe3O4, 20 – 30 nm, SkySpring
Nanomaterials, Inc.), collagen (Bovine, Type I, Life Technologies), and cells in cell
culture media were dispensed using a modified hanging drop method. Unless otherwise
noted, all spheroids were assembled using SMCs with MNPs, 20,000 cells per spheroid,
and collagen.
3.2.4. Magnetic Patterning
To assemble various shapes using magnetic force assembly, commercial magnets
(SuperMagnetMan, Birmingham, AL) of various shapes and strengths were applied to the
bottom of glass chamber slides and maintained for four days. All shapes were allowed to
fuse for four days with the magnet in place, with changes in cell culture media every
other day. Magnets were removed on the fourth day, and fused tissues were immediately
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imaged using a Nikon AZ100 multizoom microscope. Small rings were assembled using
ring magnets (2 mm OD, 1 mm ID, 1 mm thick, vendor calculated pull force = 0.16 lbs).
Medium and large rings were assembled using aligned cylinder magnets in a circular
pattern (2.5 mm diameter, 5 mm length, pull force = 1.8 lbs). Square shapes were
patterned using aligned cylinder magnets in a square pattern (2.5 mm diameter, 2.5 mm
length, pull force = 1.57 lbs). The Clemson University Tiger Paw shape was assembled
using custom cut magnetic strips. All fusion studies were performed with SMC JMCSs
composed of 0.017 mg/mL collagen, 0.3 mg/mL iron oxide MNPs, and 20,000 cells.
3.2.5. Tracking Ring Fusion
Spheroid fusion was analyzed by tracking the fusion of spheroids into a ring
(Figure 3.1). Ring magnets were commercially purchased (2 mm OD, 1 mm ID, 1 mm
thick, vendor calculated pull force = 0.16 lbs). 25 individual SMC JMCSs (0.017 mg/mL
collagen, 0.3 mg/mL MNPs, 20,000 cells) were carefully patterned around the ring
pattern in a monolayer formation. Magnets were kept in place for 48 hours and then
removed, followed by imaging with a Nikon AZ100 multizoom microscope at respective
time points. Magnet strength was varied by increasing the distance of the ring magnet
away from JMCSs (coverglass spacers placed on the bottom of the chamber slides). Four
measurements for each diameter (inner and outer) were recorded and averaged at each
time point. Samples were normalized with themselves (based on initial inner and outer
diameter measurements at 48 hours), as each sample was analyzed as the percent-initial
diameter. At least three repeats were performed for each sample.
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Figure 3.1. Studying Spheroid Fusion via Magnetic Force Assembly. Twenty-five
JMCSs were magnetically patterned and fused into a tissue ring. Ring magnets were
secured to the bottom of a chamber slide. Spheroids were magnetically patterned for 48
hours, at which point the ring magnets were removed and images were taken daily to
track the contraction and fusion of tissue rings. To vary the magnetic field force,
additional glass coverslides were placed on the bottom of chambers to increase the
distance between the magnet source and JMCSs.
3.2.6. Tissue Tube Assembly
Using a polystyrene petri dish, a long rod magnet (45 mm) composed of stacked
cylinder magnets (2.5 mm diameter, 5 mm length, pull force = 1.8 lbs) was secured to the
bottom side of the petri dish (Figure 3.2). A glass slide was placed on the top surface of
the petri dish to promote spheroid fusion. Two thousand JMCSs were added to the mediafilled petri dish and assembled on top of the magnetic template. Care was taken to seed
JMCSs evenly along the pattern. Magnetic cellular strips were incubated and allowed to
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fuse over 4 days, with media changes every other day. Next, magnetic cellular strips
were wrapped around a silicone tube (5 mm OD, 2.5 mm ID, Cole-Parmer) containing a
magnet (2.5 mm diameter, 5 mm length, pull force = 1.8 lbs) within its lumen to form a
tube tissue. To avoid oxidation of the magnet by culture media, the ends of the silicone
tube were plugged with silicone rubber. The silicone tube was rolled over the top of the
cellular strip to effectively wrap the strip around the tube. Samples were incubated in
culture media to allow more fusion for 6 additional days. To assemble bilayer tubes, two
separate magnetic cellular strips were assembled and wrapped around the same silicone
mandrel in sequential order based on the desired spatial orientation. This same technique
was applied to assemble trilayer tissue tubes. Single layer tissue tubes were assembled
using SMCs JMCSs (2,000). Bilayer tissue tubes were assembled using an internal strip
of SMC JMCSs (2,000) and an external layer of FB JMCSs (2,000). Finally, trilayer
tissue tubes were assembled using an internal strip of EC JMCSs (1,5000), medial strip of
SMCs (1,5000), and external strip of FBs (1,500). All JMCSs were composed of 20,000
cells, with 0.24 mg/mL collagen, and 0.3 mg/mL iron oxide MNPs.
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Figure 3.2. Assembly of Tissue Tube using Magnetic Force Assembly. Spheroids were
patterned, fused, and wrapped into a tube using magnetic manipulation. (A) First, JMSCs
were patterned and allowed to fuse into a homogenous strip over the course of 4 days. (B)
Next, a cylinder magnet was placed inside the lumen of a silicone tube with an outer
diameter of 5 mm. (C) Finally, the fused tissue strip was wrapped around the silicone
tube and allowed to fuse for an additional 6 days.
3.2.7. Fluorescent Labeling of Trilayer Tube
Three separate trilayer tubes were assembled, each containing one fluorescently
labeled spheroid type. Cells were fluorescently labeled in suspension prior to spheroid
assembly using a Vybrant CFDA SE Cell Tracer Kit (Life Technologies). JMCSs were
assembled for three days in a modified hanging drop as previously described, with all
JMCSs composed of 20,000 cells, 0.24 mg/mL collagen, and 0.3 mg/mL iron oxide
MNPs. Trilayer tissue tubes were assembled as previously described (1,500 spheroids per
tissue strip). However, fusion times were decreased in order to maintain fluorescent
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signal for imaging. Spheroids were seeded onto a tissue strip and allowed to fuse for 24
hours, then wrapped around a silicone tube and allowed to fuse for an additional 24
hours. Samples were fixed overnight, then histologically processed and sectioned the
following day. Tissues were permeabilized with Triton-X and stained with DAPI to
visualize nuclei. Samples were imaged using a Nikon Ti Eclipse microscope.

3.3. Results & Discussion
3.3.1. Factors Affecting Spheroid Fusion
We evaluated the ability of JMCSs to fabricate tailored 3D cell constructs and
tissues through a series of experiments utilizing magnetic assembly into a variety of
shapes (Figure 3.3 A-C, E,F). We used magnetic force manipulation to assemble shapes
with varying sizes including rings, a square, and Clemson University Tiger Paw. Results
showed that fused tissues, confirmed by a lack of voids or gaps within tissues, were
successfully assembled using variety of shapes and sizes after four days of fusion using
magnetic force assembly. Additionally, viability of fused tissue was confirmed on Day 4
by simultaneous live/dead fluorescent staining that showed no visible signs of decreased
viability, suggesting that high viability was maintained throughout tissue fusion (Figure
3.3D). While other groups have shown that magnetic cellular spheroids, which
incorporate MNPs using internalization or dispersed methods, can assemble magnetic
cellular spheroids into tailored shapes and patterns, these studies often encounter adverse
effects on cell viability and are therefore inapplicable for long-term tissue engineering
strategies [8, 9]. These results provide proof of concept for magnetically manipulated
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JMCSs to serve as building blocks in large three-dimensional tissue constructs using a
variety of shapes and sizes.
A

D

C

B

F

E

Figure 3.3. JMCSs Aligned and Fused into Homogenous Tissues using Magnetic
Force Assembly. (A-C) JMCSs were patterned and fused together into rings of varying
sizes, ranging from 2 mm (A, 25 JMCSs, scale bar = 1000 µm) up to 10 mm (B,C 3,000
JMCSs each, scale bar = 10 mm). (D) Furthermore, viability of the fused structure was
confirmed using simultaneous live/dead (green/red) fluorescent staining (scale bar = 1000
µm). (E,F) Finally, using various magnetic patterns, spheroids assembled onto custom
patterns can fuse together over the course of days to form unified constructs,
demonstrated by (E) a square and (F) Clemson University Tiger Paw. Images shown
were allowed to fuse over the course of 4 days (scale bars: E = 5 mm, F = 10 mm).
The assembly of complex 3D tissues using cellular spheroids is heavily reliant
upon efficient fusion of spheroids into a single tissue. To determine factors affecting
JMCS fusion, spheroid fusion was analyzed by tracking the fusion of spheroids into
controlled patterns using various JMCS and assembly parameters.
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When placed in

contact, cellular spheroids will fuse together, with the tissue contracting into a single
tissue construct [6]. Twenty five individual JMCSs were magnetically assembled into a
ring and their fusion was tracked. Images were taken daily and fusion was tracked by
measuring changes in the inner and outer diameters of fused tissue rings. We varied the
strength of the ring magnet to determine the effect of magnetic force on JMCS fusion to
mediate magnetic cellular spheroid fusion, as JMCSs patterned using the weakest
magnetic force (10% of maximum magnetic field) showed an increased rate of
contraction of the inner diameter compared to other samples patterned with higher
magnetic field strengths (Figure 3.4). All samples tested using 10% of the maximum
magnetic field collapsed on themselves, leaving behind no inner diameter at late time
points, results opposite of those seen using a high (100%) and medium (25%) magnetic
fields. Rings fabricated using high and medium magnetic fields fused into cohesive rings
while maintaining their desired final shape. All rings were magnetically assembled into
symmetric rings on Day 0 after initial seeding. We hypothesized that rings patterned
using 10% of the maximum magnetic field assembled into more asymmetric rings after
48 hours of fusion (with the magnet present) due to the necessity of sufficient magnetic
force for effective magnetic patterning. Additionally, we analyzed the effect of spheroid
MNP content on JMCS fusion. Results showed that similar to the strength of the
magnetic field, lower MNP content lead to a statistically significant increase in rate of
contraction (Figure 3.5) due to a decrease in the total magnetic field applied to the tissue
with lower amounts of MNPs present. However, when varying magnetic forces
(magnitude and spheroid MNP content), changes in outer diameter were not as significant
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as those seen for inner diameter measurements (Figure 3.6). Once factors affecting
spheroid assembly and fusion into complex tissues using magnetic forces are understood,
these parameters can be customized and applied for the assembly of a variety of
engineered tissues types. The dramatic reduction in internal diameter of fused rings has
been reported by other groups when analyzing fusion of cellular spheroids, while also
showing some slight differences in fusion between different cell types [17]. However, to
our knowledge, this is the first report describing the mediation of tissue contraction using
magnetic forces, possibly due to the changes of surface angle contact between spheroids
[6].

83!

A
84 hrs 108 hrs 132 hrs 156 hrs

10%

100%

Magnetic Field
60 hrs
Force

B

% Initial

100

Spheroid Ring Fusion
Varying Magnetic Field Force
Inner Diameter

100% ID
25% ID
10% ID

80
*

60

*

*

*

40
20
0
0

50

100
Time (hrs)

150

Figure 3.4. Effect of Magnetic Field Force on JMCS Fusion. (A,B) Results showed
that the strength of the magnet used for JMCS fusion played a critical role in their fusion
into the desired shape. JMCS patterning using a weak magnet (10% of maximum
magnetic field) showed a greater rate of inner diameter contraction than those patterned
using stronger magnetic fields. All samples using 10% of the maximum field collapsed
on themselves. Compared to 100% control samples, JMCSs patterned with 10% magnetic
field force demonstrated statistically significant differences at all time points after 84
hours (* p < 0.05). Scale bars = 1,000 µm.
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Figure 3.5. Effect of MNP Content on JMCS Fusion. (A,B) The MNP content within
JMCSs was varied to determine its effect on spheroid fusion. Statistical analysis showed
significant differences (* p < 0.05) for ID contraction rates at 60, 84, and 108 hrs between
the two MNP concentrations, showing that lower MNP content with JMCSs lead to a
greater rate of contraction compared to their higher MNP counterparts. Scale bar = 1000
µm.
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Figure 3.6. Factors Affecting JMCS Ring Fusion – Outer Diameter. Results showed
that the strength of the magnet used for JMCS fusion does not significantly effect
spheroid fusion regarding the OD of rings when varying (A) magnetic field force or (B)
MNP content. Statistical analysis did show significant differences when using 25%
magnetic field force compared to 100% samples at all time points after 84 hours (* p <
0.05).
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3.3.2. Assembly of Complex Tissues
Next, we expanded on the assembly of complex tissues using JMCS to assemble a
3D vascular tissue construct. Compared to top-down tissue engineering approaches,
directing tissue assembly with bottom-up approaches has become appealing due to
control over construct spatial arrangement. As the bottom-up approach is intrinsically a
modlular technique, it allows for precise control over the tissue construct
microenvironment and the ability to scale fabrication techniques [18, 19]. Results
demonstrated the ability of individual JMSCs to fuse together into a complex 3D tissue
whose assembly is driven by magnetic forces. Using magnetic forces and 2,000 to 4,000
JMCSs, spheroids were first magnetically patterned into a cellular strip, fused into a
tissue strip (Figure 3.7 A,B), and wrapped around a tube with a removable magnetic
within its lumen (Figure 3.7 C,D). Finally, the magnet within the lumen was removed,
leaving behind a fused tube tissue composed solely of JMCSs (Figure 3.7 E,F). This
method was applied to a variety of JMCS compositions, including varying cells numbers
within JMCSs (Figure 3.7 G,H), cell types (Figure 3.7I), and even multicellular
bilayered tubes using both SMCs and FBs (Figure 3.7J). The use of magnetic force
manipulation and patterning allowed for the rapid assembly of a complex tube tissue
composed of tailored cell, ECM, and MNP content using magnetic forces. The
dimensions of the vascular tissue construct are controlled by the silicone tube diameter,
cell strip length, and cell strip width. This approach allows for the assembly of a cellbased vascular tissue possessing a similar composition to native vessels by controlling
JMCS’s cell, ECM, and MNP composition.
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Figure 3.7. Assembly and Fabrication of Complex Tube Tissue. (A) Janus magnetic
cellular spheroids were assembled on top of a magnet template, (B) fused into a strip after
4 days, magnet removed (C,D) wrapped around the tube using magnetic attraction, and
(E,F) assembled as a fused tube after 6 additional days (10 days total). Additionally, this
technique was be expanded for use with: (G,H) varying cell densities, (I) cell types
(Fibroblasts, FBs), and (J) even bilayered multicellular tubes (SMC and FB, 0.24 mg/mL
collagen I).
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We next analyzed the role of time in mediating fusion of JMCSs into a complex
vascular tissue construct (Figure 3.8).

Bilayered vascular tissue constructs were

assembled and histologically analyzed after four and ten days of assembly. Results
showed that fusion time is critical in assembling complex tissues, as samples analyzed at
day four still presented individual spheroids within the tissue core. Samples analyzed at
day ten showed clear fusion of individual JMCSs into a single fused tissue. Kelm et al.
showed that the application of fluid flow to the lumen of the fused tissue led to an
increased fusion of assembled spheroids into a tissue tube after 14 days [20]. Here, we
demonstrated that by applying magnetic forces during fusion, we can effectively control
the fusion of JMCSs into a single fused tissue without fluid flow.
Masson’s Trichrome

Magnified View

Day 10

Day 4

H&E

Figure 3.8. Fusion of Complex Tube Tissue. Bilayer tissue tubes were assembled using
four thousand JMCSs (2,000 SMCs, 2,000 FBs) and revealed that fusion time is
important for tissue assembly, as tissues at day four still presented individual JMCSs
(scale bar = 5 mm, magnified = 500 µm).
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Complex tissue tubes composed of multiple cell types were assembled to evaluate
the potential for tailored JMCSs to assemble a functional vascular tissue construct. Using
magnetic force assembly, thousands of JMCSs were assembled into a fused tissue tube 5
mm in diameter. As a proof of concept, a tissue tube mimicking both the spatial
composition and content of a small diameter blood vessel was assembled. Tissue tubes
were analyzed using histological staining to visualize the spatial localization of collagen
and cells within the tissues. First, a unilayer tube composed of solely SMCs was
assembled (Figure 3.9A). Next, a bilayer tube composed of an internal layer of SMCs
and an external layer of FBs was fabricated using the same method (Figure 3.9B).
Ultimately, a trilayer tube composed of an internal layer of endothelial cells, medial layer
of SMCs, and external layer of FBs was assembled (Figure 3.9C). Cells were spatially
oriented in this manner to mimic the tunica intima (endothelial cells), tunica media
(SMCs) and tunica adventitia (FBs) of native blood vessels. Furthermore, analysis was
performed to confirm control over the spatial location of cells within assembled tissues.
Three separate trilayer tubes were assembled, with one cell type labeled within each tube.
Results showed that the spatial location of different cell types could be tailored to mimic
that orientation of native vascular tissues, confirmed by an external layer of FBs (Figure
3.9D), medial layer of SMCs (Figure 3.9E), and internal layer of ECs (Figure 3.10F).
All tissue tubes were assembled using cellular spheroids containing 0.24 mg/mL
collagen. Tissue tubes were assembled using high collagen spheroids in order to maintain
a patent lumen due to the structural and mechanical properties provided by collagen.
Other groups have demonstrated spatial control of multicellular vascular tissue
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constructs, but require complex printing equipment for assembly [21]. Additionally, this
approach to wrap a magnetic cell sheet around a magnetic mandrel has been previously
utilized to assemble multicellular tissue tubes [22].

However, Ito et al. induced

internalization of MNPs into cells prior to cell sheet assembly, and will likely encounter
adverse effects related to MNP uptake in long-term applications [23, 24]. The presented
strategy to assemble multicellular vascular tissue constructs demonstrates a simplistic and
cheap approach to spatially control tissue engineered building blocks into tissue tubes.
This strategy can be applied to any building blocks capable of magnetic force
manipulation assembly. Furthermore, the use of JMCSs, which have been shown to
reduce adverse effects on cell phenotype and viability, are appealing for tissue
engineering strategies which require long-term interaction between MNPs and cells.
To further justify the use of high collagen spheroids for tissue tube assembly, the
mechanical stability of tissue tubes was analyzed. Bilayer tissue tubes were assembled
using both high (0.24 mg/mL) and low (0.017 mg/mL) collagen spheroids as previously
described. Results showed that upon removal of the tissue tubes from the mandrel after
day ten of assembly, low collagen tubes immediately collapsed (Figure 3.10).

In

contrast, high collagen tissue tubes remained open and patent upon removal from the
mandrel.

These high collagen tubes were self-retaining and capable of physical

manipulation while low collagen tubes were incapable of physical handling. Therefore,
due to the immediate collapse and inability for physical handling, low collagen tissue
tubes were inadequate as a functional tissue engineered construct. These results suggest
that in addition to mediating fusion, collagen content plays a critical role for structural
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support when fabricating complex tissue structures composed of fused spheroids. An
advantage of tissue engineering with spheroids is that fusion can occur within days, but
the mechanical properties of the tissues tend to be inadequate [5]. Collagen provides a
natural scaffold for the fusing tissue at its early stages, which allows the tissues to
maintain structure and potentially be handled for introduction into post-processing
techniques for maturation [2].
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Figure 3.9. Assembly of Vascular Tissue Construct using JMCSs. Tissue tubes were
successfully assembled using JMCSs to fabricate tubes composed of one, two and three
different cell types to mimic the spatial orientation of cells within a blood vessel. (A) A
single layer tissue tube composed of SMCs alone was assembled. (B) Next, a bilayered
tissue tube composed of an internal layer of SMCs and an external layer of FBs was
assembled. (C) Finally, a trilayered tissue tube composed of an internal layer of ECs, a
medial layer of SMCs, and an external layer of FBs was assembled using magnetic force
assembly. (D-F) To confirm the presence of three distinct cell types in different spatial
locations, three separate trilayer tubes were assembled and analyzed (L = lumen). For
each tube, one different cell type was labeled prior to tissue assembly (green). The whole
tissue was stained for nuclei to visualize the location of other non-labeled cells and tissue
tube boundaries. Results showed that three different cell types could be incorporated into
a trilayer tube, demonstrating spatial control over the orientation of each cell type to
mimic the native orientation found in vascular tissues. Results indicate that JMCSs can be
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successfully fabricated into tissue tubes mediated by magnetic forces and incorporate
multiple cell types with control over spatial alignment of cells and tissue composition.
Scale bars: A-C = 5 mm, D-F = 500 µm

Bilayer Tissue Tube
FB + SMC

Collagen
Concentration 0.017 mg/mL

0.24 mg/mL

Figure 3.10. Effect of Collagen Content on Tissue Tube Structural Support. Bilayer
tissue tubes were assembled with high (0.24 mg/mL) and low (0.017 mg/mL) collagen
contents to determine the role of collagen in structural support. Results showed that
collagen content plays a critical role in structural integrity, as low collagen tissue tubes
collapsed upon removal from the mandrel template, while high collagen tissue tubes
remained open and capable of physical handling.
3.4. Conclusions
We demonstrated that JMCSs can be used to successfully assemble and
manipulate spheroids into controlled patterns and mediate their fusion over time, a
strategy that can be used to assemble larger 3D tissue constructs. These results show that
it is critical to control the magnetic forces to mediate fusion of tissues using magnetic
cellular spheroids. The ultimate goal of this technology will be the assembly of larger
tissue structures using magnetic force assembly, with the additional opportunity to use
magnetic forces and manipulation for tissue construct maturation. While the ability to
tailor the ECM and cellular content and composition of cellular spheroids makes them
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applicable for tissue engineering, care must be taken when designing tissues in order to
optimize tissue fusion based off the spheroid formulation used.
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CHAPTER 4
BIOLOGICAL MAGNETIC CELLULAR SPHEROIDS AS BUILDING BLOCKS FOR TISSUE
ENGINEERING
4.1. Introduction
A variety of nanoparticles (NPs) including magnetic iron oxide NPs, gold NPs,
carbon nanotubes, and polymeric NPs have been integrated with tissue engineering to
provide in situ imaging, drug delivery, mechanical properties, and functionality [1, 2].
Nanotechnology can benefit tissue engineering due to its ability to control interactions at
sub-cellular levels that are not possible using common tissue engineering techniques [35]. Particularly, magnetic nanoparticles (MNPs) have been integrated with tissue
engineering applications for tissue patterning and maturation [6-9]. However, the direct
and long-term interaction of MNPs with cells can induce ad5verse effects on cell
viability, phenotype, and function, and therefore remain a critical concern. Commonly
investigated MNPs include ferrites (cobalt [10], manganese [11], nickel [12]),
manganites, as well as metals (Fe [13], Co, Ni [14]) and their alloys. However, before
these ferrite NPs may be used in biomedical applications, their surfaces must be modified
with polymers [15], gold, or silica [16] to improve or reduce their toxicity. Because of the
complex chemistry inherent in such modifications, there is a critical need to investigate
biological MNPs as an alternative to commonly used iron oxide MNPs which effectively
reduce adverse effects on cells, thereby allowing for long-term use in tissue engineering
applications.
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Magnetoferritin is a potential biological MNP that can address the adverse
cellular effects of common metallic MNPs. The primary role of ferritin, a natural protein
in the body, is iron storage, with normal blood serum levels ranging from 10-200 ng/mL,
and mean values of 103 ng/mL and 35.6 ng/mL for males and females, respectively [17].
In this work, we attempted to elucidate how to use magnetoferritin NPs to serve as a
biological alternative to iron oxide MNPs. Specifically, we prepared magnetoferritin NPs
with tailored loading and magnetic properties, analyzed its effects on cell viability, and
demonstrated its ability to mediate tissue patterning via magnetic force assembly. The
results demonstrate that magnetoferritin NPs have the potential to mitigate the
cytotoxicity that currently prevents prolonged use of MNPs in tissue engineering
applications.

4.2. Materials & Methods
An overview of experimental procedures, parameters, and objectives can be found
in Table 4.1.
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Experiment
Synthesize Tailored
Magnetoferritin NPs

Parameters

Objective

•Synthesis Cycles
•MNP Loading

•Control the loading of MNPs into
Magnetoferritin NPs to tailor their
magnetic properties

•Method to incorporate
Magnetoferritin NPs
•Dispersed
•Uptake
•Magnetoferritin Content

•Analyze spatial location of
Magnetoferritin NPs within cellular
spheroids

MNP Loading
Histological Examination
of Magnetoferritin NPs in
Magnetoferritin Cellular
Spheroids

*All samples analyzed on Day 3
Internalization of
MNPs in Magnetic
Cellular Spheroids

•Method to incorporate
Magnetoferritin NPs
•Dispersed
•Uptake

•Quantify the internalization of
Magnetoferritin NPs into cells using
two different magnetic cellular spheroid
techniques

*All samples analyzed on Day 3
Magnetoferritin NP
Toxicity in Magnetoferritin
Cellular Spheroids

•Method to incorporate
Magnetoferritin NPs
•Dispersed
•Uptake

•Determine effect of Magnetoferriin NPs
on cell viability within magnetic cellular
spheroids

*Samples analyzed on Days 3 and 7
Magnetic Force Assembly •MNP
Using Magnetoferritin
•Magnetoferritin
Cellular Spheroids
NPs
•Iron Oxide NPs

•Analyze the capacity of Magnetoferritin
NPs to be utilized for magnetic force
assembly in tissue engineering
applications
*Samples analyzed Day 4 fusion

Cell

Magnetic Cellular Spheroid

MNP

Ring Magnet

ECM

Glass Coverslide

Table 4.1. Experimental Plan for Magnetoferritin Synthesis and Evaluation.
Experiments were performed to synthesize magnetoferritin NPs with tailored MNP
content, analyze the interaction of magnetoferritin NPs with cellular spheroids based
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histological examination to visualize spatial localization, quantification of internalization
into cells, viability of cells within cellular spheroids, and the ability for magnetoferritin
cellular spheroids to be utilized for magnetic force assembly in tissue engineering
applications.
4.2.1. Materials
Apoferritin (equine spleen), Trimethylamine-n-oxide ((CH3)3N(O), 98%),
AMPSO

(C7H17NO5S,

99%),

ammonium

(II)

sulfate

hexahydrate

((NH4)2Fe(SO4)2!6H2O, 99%), and potassium ferrocyanide (K4Fe(CN)6!3H2O, 98.5102%) were supplied by Sigma-Aldrich. Hydrocholoric acid (HCl, 6 N) was supplied by
Ricca Chemical Company. PrestoBlue Cell Viability Reagent and Collagen, Type I
Bovine were supplied by Life Technologies. Commercial iron oxide MNPs were supplied
by SkySpring Nanomaterials, Inc. (Fe3O4, 20 – 30 nm).
4.2.2. Statistical Analysis
All statistical analysis was performed using a two-tailed t-test with at least three
repeats each. Statistical significance was set at p < 0.05. Error bars on graphs represent
the standard deviation from the mean.
4.2.3. Magnetoferritin Synthesis
Magnetoferritin NPs were synthesized by gradually loading apoferritin with iron
oxide NPs [18].

Apoferritin (0.44 M) was placed in a 3-[(1,1-Dimethyl-2-

hydroxyethyl)amino]-2-hydroxy-propanesulfonice acid (AMPSO) buffer solution (50
mM, pH 8.6) and heated to 65 °C. Aliquots of ferrous ammonium sulfate (Fe2+, 0.1 M)
and triemethylamine-N-oxide (Me3NO, 0.07 M) were added dropwise to the reaction
solution. Each addition of Fe(II) (0.612 µmol) was followed by a stoichiometric aliquot
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of Me3NO (3 Fe(II): 2 Me3NO, 0.612 µmol : 0.41 µmol) and stirred for 15 minutes before
repeating the stepwise addition. Samples were dialyzed in water at 4 °C for two days
prior to use.
4.2.4. Magnetoferritin NP Characterization
A bichinchoninic acid (BCA, Lambda Biotech, Inc.) assay was performed to
quantify the amount of protein. Iron content within magnetoferritin NPs was quantified
using an established technique to quantify iron content in solutions [19]. Briefly, NPs
were first dissociated using 5 N HCl, followed by quantification of free iron within
solutions

using

a

Perl’s

Prussian

blue

colorimetric

technique.

Additionally,

magnetoferritin NPs were characterized using scanning transmission electron microscopy
(STEM) and energy dispersive spectrometry (EDS) on a Hitachi 2000 STEM scope.
4.2.5. Cell Culture
Primary rat aortic smooth muscle cells (SMCs) were used for all cellular spheroid
studies. Cells were cultured in monolayer cultures using Dulbeco’s Modified Eagle
Medium:F-12 (ATCC, 1:1, DMEM:F-12) supplemented with 10% fetal bovine serum
(Atlanta Biologics) and 1% penicillin-streptomycin-amphotericin (MediaTech, Inc.) at 37
°C and 5% of CO2.
4.2.6. Cellular Spheroid Assembly
To assemble cellular spheroids, MNPs (magnetoferritin NPS or iron oxide NPs),
collagen (Bovine, Type I, Life Technologies), and cells in cell culture media were
dispensed using a modified hanging drop method. Unless otherwise noted, all spheroids
were assembled using SMCs with MNPs, 20,000 cells per spheroid, and collagen.
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Commercial iron oxide MNPs were used (Fe3O4, 20 – 30 nm, SkySpring Nanomaterials,
Inc.).
4.2.7. Quantification of NP Uptake
First, cellular spheroids (10, Dispersed and Uptake) were dissociated. Dissociated
samples were suspended in 1 mL fresh media and placed on a magnetic wash tool for five
minutes. The supernatant was collected, and the remaining cells (magnetically attracted)
suspended in 1 mL fresh media. The amounts of cells in the supernatant and magnet
solution were quantified using a hemocytometer. Spheroids were collected and analyzed
after three days of assembly in hanging drop.
4.2.8. Cellular Spheroid Viability
Magnetoferritin NP cellular spheroids were fabricated with 500 µg/mL
magnetoferritin NPs and compared to control cellular spheroids without magnetoferritin
NPs and spheroids with iron oxide MNPs. PrestoBlue cell viability assays were
performed to quantify cell viability after spheroid dissociation (at least 3 repeats per
sample).
4.2.9. Histology
Magnetoferritin cellular spheroids were processed and sectioned via standard
paraffin sectioning techniques. Samples were dehydrated using ethanol and xylene prior
to being embedded in paraffin. Sections 5 µm thick were stained with hematoxylin and
eosin, and Lillie’s Technique for Turnbull's Blue Reaction (Poly Scientific).
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4.2.10. Magnetic Patterning
Commercial ring magnets (SuperMagnetMan, 10 mm diameter), were secured to
the bottom of glass chamber slides. Four hundred magnetic cellular spheroids were
placed in the chamber and allowed to magnetically align. Tissue structures were allowed
to fuse for four days prior to imaging, and magnet patterns were kept static throughout
the four days and removed for imaging. Samples were imaged using a Nikon AZ100
multizoom microscope. Different concentrations of magnetoferritin NPs and iron oxide
MNPs were used due to the magnetic attraction of cellular spheroids.

4.3. Results & Discussion
4.3.1. Magnetoferritin Synthesis & Characterization
By varying the number of cycles (from 10 to 70) performed during
magnetoferritin NP synthesis, we were able to tailor the loading of iron oxide into equine
spleen apoferritin protein shells. By increasing the number of synthesis cycles, we
increased the iron oxide loading per ferritin shell from 810 to 3395 (iron oxide per
protein, Figure 4.1A). Additionally, by varying the iron oxide content within
magnetoferritin NPs, we were able to control the magnetic properties of these biological
MNPs, as a higher loading content corresponded to stronger superparamagnetic
properties with the application of an external magnetic field. In our subsequent analysis
of our magnetic manipulation of magnetoferritin NPs, we determined that 70 cycle
magnetoferritin NPs were subject to magnetic manipulation and attraction in contrast to
unloaded apoferritin NPs (Figure 4.1A).
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Furthermore, magnetoferritin NPs were

characterized using scanning-transmission electron microscopy (STEM) and energydispersive spectroscopy (EDS, Figure 4.1B). Z-contrast was used for STEM imaging to
highlight the iron oxide cores from their protein shell. Results confirmed that
magnetoferritin NPs contained iron oxide, as indicated by the presence of both iron (red)
and oxygen (blue) compared to apoferritin controls in EDS analysis. We used EDS to
quantitatively confirm the iron content from magnetoferritin formulations, as
demonstrated by an atomic percent increase of iron for 10 and 70 cycle magnetoferritin
NPs (12.6% and 29.5%, respectively) compared to unloaded apoferritin (0.52%). The
small amount of iron present in apoferritin samples was likely due to residual iron from
the unloading of the native ferritin NPs. By controlling the loading of iron oxide into
apoferritin shells and therefore the magnetic properties of magnetoferritin NPs, we
demonstrated the ability to prepare tailored biological magnetic NPs.
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Figure 4.1. Characterization of Magnetoferritin Nanoparticles. (A) The loading of
iron oxide into magnetoferritin NPs was successfully controlled and resulted in magnetic
NPs (70 cycle, compared to unloaded apoferritin protein NPs). Results confirmed control
over loading content into magnetoferritin NPs based on reaction cycles performed. (B)
Magnetoferritin NPs were analyzed using STEM and EDS to confirm the presence of an
iron oxide core, as noted by the high expression of iron and oxygen in magnetoferritin
NPs compared to apoferritin protein shells. Magnetoferritin NPs were characterized by an
atomic weight percent increase in iron between 10 (12.6%) and 70 cycle (29.5%)
magnetoferritin NPs, confirming an increased presence of iron oxide.
Scale bars:
apoferritin, 10 cycle = 600 nm, 70 cycle = 300 nm.
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4.3.2. Magnetoferritin Cellular Spheroids
To determine the capacity for magnetoferritin NPs to serve as effective magnetic
NPs for tissue engineering applications, magnetoferritin NPs were incorporated into
cellular spheroids. Specifically, using rat aortic smooth muscle cells, magnetoferritin NPs
(70 cycles) were incorporated into cellular spheroids using two techniques: uptake and
dispersed (Figure 4.2A). Uptake cellular spheroids refer to spheroids composed of cells
that have internalized magnetoferritin NPs.

Dispersed cellular spheroids refer to a

method of spheroid synthesis in which magnetoferritin NPs are dispersed throughout the
extracellular space.

Histological analysis was performed to analyze the dispersion of

magnetoferritin NPs within cellular spheroids (Figure 4.2B). Samples were stained using
hemotoxylin and eosin (H&E), and Lillie’s Turnbull Blue Reaction to show the presence
of iron oxide within magnetoferritin NPs (iron = black). Magnetoferritin was visible in
both stains, appearing red-orange in H&E, and black in Lillie’s Turnbull Blue Reaction.
Results confirmed the dispersion of magnetoferritin NPs throughout the cellular
spheroids using both spheroid formulations (uptake and dispersed) at magnetoferritin
concentrations of 82 µg/mL. Furthermore, as the internalization of iron oxide MNPs into
cells can induce cytotoxic effects, interaction between cells and MNPs should be
minimized [20]. Compared to iron oxide MNPs, results showed that the percentage of
cells internalizing magnetoferrtin NPs with dispersed cellular spheroids was significantly
lower (14%) than that of iron oxide MNPs (28%) (Figure 4.2C). Additionally, multiple
magnetoferritin NP contents were histologically analyzed (Figure 4.3). These results
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indicate that magnetoferritin NPs can be effectively incorporated within magnetic cellular
spheroids with reduced internalization into cells.
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Figure 4.2. Magnetoferritin Nanoparticles in Magnetic Cellular Spheroids. (A)
Magnetoferritin NPs were incorporated into cellular spheroids using two methods: uptake
and dispersed. Uptake spheroids contain cells that have internalized magnetoferritin NPs,
while dispersed spheroids contain magnetoferritin NPs spatially distributed throughout
the extracellular space. (B) Histological examination confirmed the assembly of cellular
spheroids using both methods. Samples were stained with H&E and Lillie’s Technique
for Turnbull’s Blue Reaction (Iron) to visualize the location of magnetoferritin NPs
(Scale bar = 500 µm). (C) Using dispersed cellular spheroids, results showed that
magnetoferritin NPs resulted in significantly lower cell uptake compared to iron oxide
MNPs (* p < 0.05).
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10 µg/mL

20 µg/mL

41 µg/mL

H&E

Iron

Figure 4.3. Tailored Magnetoferritin Content in Cellular Spheroids. Cellular
spheroids containing various amounts of mangetoferritin were histologically examined
using H&E and Lillie’s Technique for Turnbull’s Blue Reaction (Iron) to confirm control
over magnetoferritin content (Scale bar = 500 µm). Results showed that magnetoferritin
content can be tailored during spheroid fabrication, confirmed by an increase in iron
content (black, Iron) as magnetoferritin concentrations were increased from 10 µg/mL up
to 41 µg/mL.
To determine if magnetoferritin NPs induced cytotoxic effects on cells, we
analyzed the cell viability of magnetoferritin spheroids. In our examination of both
spheroid types composed of 500 µg/mL magnetoferritin, we confirmed that the presence
of magnetoferritin NPs did not adversely affect cell viability compared to controls
without MNPs (Figure 4.4A). Notably, we maintained a high cell viability using
magnetoferritin NPs as compared to conventional metallic iron oxide MNPs (20-30 nm)
up to one week. Using metallic iron oxide MNPs at concentrations of 50 µg/mL, Ho et al.
demonstrated noticeable toxicity in patterned cellular spheroids after only 48 hours,
thereby preventing potential use in tissue engineering applications that require a longterm interaction with biological systems to be clinically applicable [6]. Unlike iron oxide
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MNPs, magnetoferritin NPs are composed of a protein shell, which makes them quite
suitable for the long-term interaction with biological systems for tissue engineering
applications. Therefore, magnetoferritin NPs can serve as an alternative biocompatible
magnetic NP to iron oxide MNPs.
Finally, to demonstrate the application of magnetoferritin NPs for tissue
engineering, we prepared fused tissue rings as a model using magnetic force assembly.
We first confirmed the magnetic attraction of magnetoferritin cellular spheroids (Figure
4.4B), and then magnetically patterned and fused these dispersed magnetoferritin cellular
spheroids (500 µg/mL) over a four day period into a tissue ring (Figure 4.4C). Samples
were compared to magnetic cellular spheroids with iron oxide MNPs as a control (300
µg/mL). Fusion was confirmed by the lack of individual cellular spheroids after four days
of patterning, which formed a single homogenous tissue void of gaps upon removal of the
magnetic pattern. Based on these results, magnetoferritin can serve as a biological
alternative to metallic MNPs for magnetic force assembly of tissues.
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Figure 4.4. Magnetoferritin Cellular Spheroids for Tissue Engineering. (A)
Magnetoferritin cellular spheroids were compared to control cellular spheroids without
any magnetic NPs and iron oxide MNP cellular spheroids. Results confirmed that high
viability was maintained up to one week compared to control spheroids without MNPs
and magnetic cellular spheroids using iron oxide MNPs (* p < 0.05). (B) The ability of
magnetoferritin cellular spheroids to magnetically attract to a permanent magnet was
confirmed (magnet diameter = 10 mm). (C) Using magnetic force assembly, results
showed a fused homogenous tissue, with magnetoferritin serving as a comparable
alternative to iron oxide magnetic MNPs for patterning and fusion. Scale bar = 10 mm.
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4.4. Conclusions
In conclusion, we have demonstrated that NPs can safely be integrated with tissue
engineering applications using magnetoferritin NPs and serve as an alternative to iron
oxide MNPs. The biological nature of magnetoferritin NPs has been shown to have the
most potential in applications requiring long-term interaction with biological systems in
that they exhibit no adverse effects on cell viability at concentrations much higher than
that used with other metallic MNPs.

In future research, we will expand upon our

magnetoferritin NPs to fabricate complex three-dimensional tissue structures, multicellular tissues, study long-term biological response to cells, and test remote control of
magnetic spheroids using magnetic forces.
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CHAPTER 5
ACCELERATED IRON OXIDE NANOPARTICLE DEGRADATION MEDIATED BY POLYMER
ENCAPSULATION WITHIN CELLULAR SPHEROIDS
5.1. Introduction
A variety of nanomaterials including gold nanoparticles, carbon nanotubes,
polymeric nanoparticles, and magnetic iron oxide nanoparticles have been used in various
tissue engineering strategies involving imaging, tissue maturation and integration, and
drug delivery [1-9]. Magnetic nanoparticles (MNPs) are now being increasingly used in
biomedical applications [10-20], with some FDA approved iron oxide MNP formulations
used to treat iron deficiency (Feraheme) or as MRI contrast agents (Feridex) [21-23].
MNPs have been investigated in tissue engineering applications for in vivo cell tracking
[24-29], in vivo monitoring of transplanted tissues [30-32], cell and tissue patterning [11,
13, 15], and tissue maturation [33]. However, the prolonged presence of MNPs can
induce adverse effects in cells, causing cell toxicity, and changes in both cell phenotype
and cell mobility [13, 34, 35]. Though the surface functionalization or coating of MNPs
in oleates [36, 37], dextran [23, 38], or polymers [31, 39] can improve MNP
biocompatibility, they do not control the MNP degradation. Ideally, MNPs will remain
stable for a sufficient time to accomplish their desired task, and then rapidly degrade once
their task is completed.
A variety of different chemicals, primarily organic acids, have been investigated
to accelerate the degradation of iron oxide MNPs [40-44]. In these experiments, after the
MNPs accomplished their desired task, the accelerated MNP degradation decreased their
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interaction with cells. Here, we report the precise control of iron oxide MNP degradation
via MNP encapsulation within biodegradable polymers for tissue engineering
applications. Iron oxide MNPs encapsulated within polymeric nanoparticles are a
biodegradable alternative to non-coated MNPs to remove MNP in situ in that they
obviate potential toxicities. By accelerating MNP degradation, they may have broad use
in medical devices, drug delivery, and bioimaging agents composed of iron oxides.

5.2. Materials & Methods
An overview of experimental procedures, parameters, and objectives can be found
in Table 5.1.

116!

Experiment

Parameters

Objective

Assemble PolyMNPs

•Determine capacity to assemble
•Polymer
polymer encapsulated MNPs with
•PLA-PEG
different polymer NPs and tailor the
•PLGA(75/25)-PEG
•Encapsulation Efficiency loading of MNPs into polymer NPs

PolyMNP Degradation –
Polymer Composition

•Time
•Polymer
•PLA-PEG
•PLGA(75/25)-PEG

•Determine the effect of polymer
composition on MNP degradation
within PolyMNPs

*Samples analyzed weekly
PolyMNP Degradation –
Polymer Content

•Time
•Determine the effect of polymer content
•Encapsulation Efficiency on MNP degradation within PolyMNPs

*Samples analyzed weekly
PolyMNP Cellular
Spheroid Viability

•Time
•Polymer
•PLA-PEG
•PLGA(75/25)-PEG

•Determine effect of PolyMNPs on cell
viability within magnetic cellular
spheroids
*Samples analyzed Day 3, 7, 14

PolyMNP Cellular
Spheroids for Magnetic
Patterning

•Polymer
•PLA-PEG
•PLGA(75/25)-PEG

•Analyze the capacity of PolyMNPs to be
utilized for magnetic for assembly in
tissue engineering applications

*Samples analyzed 48 hrs fusion
Hydrophobic Polymer

Cell

Magnetic Cellular Spheroid

Hydrophilic Polymer

ECM

Ring Magnet

MNP

Glass Coverslide

Table 5.1. Experimental Plan for PolyMNP Analysis. Experiments were performed to
analyze the ability to tailor the encapsulation of MNPs inside polymeric NPs, determine
the effect of polymer composition and content on MNP degradation, determine the effect
of PolyMNPs on cell viability within magnetic cellular spheroids, and to utilize
PolyMNP cellular spheroids for magnetic force assembly. Multiple parameters were
varied within each experiment as noted.
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5.2.1. Materials
Commercial MNPs (Fe3O4, 20 – 30 nm) were supplied by SkySpring
Nanomaterials, Inc. D,l lactide (C6H8O4, PURASORB DL) was supplied by Purac
Biomaterials.

Glycolide

(C4H4O4,

>99%),

tin(II)

2-ethylhexanoate

([CH3(CH2)3CH(C2H5)CO2]2Sn, ~95%), sodium sulfate (Na2SO4,, >99%), anhydrous
magnesium sulfate (MgSO4, >99.5%), anhydrous toluene (C6H5CH3, 99.8%), methanol
(CH3OH, >99.9%), chloroform (CHCl3, >99.8%), and potassium ferrocyanide
(K4Fe(CN)6!3H2O,

98.5-102.5%)

were

supplied

by

Sigma-Aldrich.

Methoxy-

poly(ethylene glycol) was supplied by JenKem Technology USA (M-PEG-OH, Mw
5000).

Acetonitrile (C2H3N, 99.9%) and Tetrahydrofuran (C4H8O,, 99.9%)

were

supplied by Fisher Scientific. Hydrocholoric acid (HCl, 6 N) was supplied by Ricca
Chemical Company. PrestoBlue Cell Viability Reagent and Collagen, Type I Bovine
were supplied by Life Technologies.
5.2.2. Statistical Analysis
All statistical analysis was performed using a two-tailed t-test with at least three
repeats each. Statistical significance was set at p < 0.05. Error bars on graphs represent
the standard deviation from the mean.
5.2.3. Polymer Synthesis & Characterization
Block copolymers of PLA-PEG or PLGA-PEG were synthesized via ring opening
polymerization using methoxy-poly(ethylene glycol) as the initiator and tin(II) 2ethylhexanoate as the catalyst [45]. PLGA composition was controlled by varying the
ratio of d,l lactide and glycolide. Reagents were dissolved by stirring in 120 °C toluene
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under N2 gas and reflux. Tin(II) 2-ethylhexanoate was added and reaction vessel was
stirred at 120 °C for 24 hours. The next day, polymer product was washed in
chloroform/water, dried over MgSO4, and precipitated in cold methanol. NMR was
performed with a Bruker Avance 300. 1H NMR (300 MHz, CDCl3, !): 7.26 (s, CDCl3),
5.17 (q, -C(=O)-CH(CH3)-), 4.82 (d, -C(=O)-CH2-O-), 3.65 (s, -CH2CH2-O-), 1.59 (d, CH(CH3)-). ATR FT-IR was performed with a Thermo-Nicolet Magna 550 equipped
with a Thermo-SpectraTech Foundation series Endurance Diamond ATR. IR: 2881 cm-1
(-CH2CH2-O-), 1745 cm-1 (C=O). TGA was performed on a TA Instruments Hi-Res TGA
2950 thermogravimetric analyzer under nitrogen from 25 °C to 600 °C at 20 °C/min.
5.2.4. Polymer Degradation
Polymers were dissolved in acetonitrile (ACN, 50 mg/mL) and dispensed into a
non-treated 96-well plate (125 µL, 6.25 mg). Plates were left overnight under a chemical
hood to evaporate ACN, leaving behind a polymer film. Wells were filled with PBS and
incubated at 37 °C until their respective time point. At each time point, PBS was
removed and samples were washed three times with Hyclone Molecular Biology Grade
Water (Fisher Scientific). Samples were dissolved in ACN and collected to be dried via
lyophilization. The Polymer Molecular Weight was determined through gel permeation
chromatography (GPC) on a Waters 1525 Binary HPLC pump with a Waters 2414
refractive index detector. A Shodex KF-804L column (8.0 x 300 (mm) ID x Length) and
Shodex KF guard column were used for separation. The mobile phase was
tetrahydrofuran (THF) and polymers were prepared by dissolving in THF at a
concentration of 1 mg/mL and filtering through a 0.2 µm PTFE syringe filter (VWR
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International). Flow rate was set at 1 mL/min and polystyrene standards (Poly-Sciences)
were used to quantify molecular weight using a third-order fit calibration curve. The MW
of samples at each time point was expressed as a percent initial.
5.2.5. PolyMNP Encapsulation
MNPs were encapsulated into polymeric nanoparticles via solvent evaporation
[46]. Briefly, equal volumes of polymer (5 mg/mL) and iron oxide were dispersed in
ACN and combined with Hyclone Molecular Biology Grade Water at a 1:2 ratio.
Solutions were stirred for two hours, then washed in centrifugal filter units (100 kD
MWCO, 3,500 RPM for 8 minutes) twice with water, and once with PBS. Final solutions
were suspended in cell culture media or PBS depending on the application.
5.2.6. Cell Culture
Primary rat aortic smooth muscle cells (SMCs) were used for all cellular spheroid
studies. Cells were cultured in monolayer cultures using Dulbeco’s Modified Eagle
Medium:F-12 (ATCC, 1:1, DMEM:F-12) supplemented with 10% fetal bovine serum
(Atlanta Biologics) and 1% penicillin-streptomycin-amphotericin (MediaTech, Inc.) at 37
°C and 5% of CO2.
5.2.7. PolyMNPs in Cellular Spheroids
To assemble JMCSs, MNPs (PolyMNP or iron oxide NPs), collagen (Bovine,
Type I, Life Technologies), and cells in cell culture media were dispensed using a
modified hanging drop method. Unless otherwise noted, all spheroids were assembled
using SMCs with MNPs, 20,000 cells per spheroid, and collagen. Commercial iron oxide
MNPs were used (Fe3O4, 20 – 30 nm, SkySpring Nanomaterials, Inc.).
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5.2.8. Quantification of PolyMNP Degradation
Iron content within cellular spheroids was quantified using an established
technique to quantify that content in solutions [47]. Briefly, MNPs were first dissociated
using 5 N HCl, followed by quantification of free iron within solutions using a Perl’s
Prussian blue colorimetric technique. Magnetic cellular spheroids containing PolyMNPs
(0.13 – 0.2 mg/mL) were fabricated and incubated in non-treated 96-well plates in cell
culture media with media changes every other day. At each time point, cellular spheroids
were transferred to 1 mL of sterile PBS in a sterile 1.5 mL microcentrifuge tube to wash
samples. Spheroids were then transferred into 100 µL fresh PBS in a non-treated 96-well
plate. 100 µL of 5 N HCl was added to each well and incubated at 37 °C for 72 hours to
dissociate MNPs. Next, 100 µL of 5% potassium ferrocyanide was added to each well
and incubated for 15 minutes at room temperature, with absorbance measurements
recorded at 630 nm for each well.
5.2.9. Cellular Spheroid Viability
PolyMNP cellular spheroids were fabricated with 0.5 mg/mL PolyMNP and
compared to control cellular spheroids without PolyMNPs. PrestoBlue cell viability
assays were performed to quantify cell viability (at least 3 repeats per sample). Spheroids
were dissociated via incubation with collagenase at 37 °C (Collagenase Type IV, Life
Technologies).

Cellular spheroids were then physically dissociated and allowed to

adhere overnight on a tissue culture treated 12-well plate.
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5.2.10. Histology
PolyMNP cellular spheroids were processed and sectioned via standard paraffin
sectioning techniques. Samples were dehydrated using ethanol and xylene prior to being
embedded in paraffin. Sections 5 µm thick were stained with hematoxylin and eosin, and
Lillie’s Technique for Turnnbulls Blue Reaction (Poly Scientific).
5.2.11. Magnetic Patterning & Fusion
Axially magnetized ring magnets (SuperMagnetMan, 2 mm OD, 1 mm ID, vendor
calculated pull force = 0.16 lbs).) were commercially purchased and secured to the
bottom of glass chamber slides containing coverglass bottoms. Twenty-five magnetic
cellular spheroids (0.14 mg/mL PolyMNP) were placed in the chamber and allowed to
magnetically align.

Samples were incubated at 37 °C with 5% CO2 for 48 hours.

Magnets were removed after 48 hours and samples imaged using a Nikon AZ100
multizoom microscope.

5.3. Results & Discussion
5.3.1. Polymer Encapsulated MNPs (PolyMNPs)
MNPs were loaded into polymeric NPs using a solvent evaporation technique
with two different polymers, poly(lactide)-poly(ethylene glycol) (PLA-PEG) and
poly(lactide-co-glycolide)-poly(ethylene glycol) (PLGA-PEG), and purified to eliminate
free polymer and free MNPs to form PolyMNPs (Figure 5.1A). The generation of
polymer degradation byproducts, lactic and glycolic acid, created an acidic
microenvironment within the polymeric NPs [48]. Furthermore, the dissolution of iron
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oxide by acids occurred in three primary steps: the adsorption of organic ligands on the
iron oxide surface, then non-reductive dissolution, and finally reductive dissolution
(Figure 5.1B) [44]. FT-IR analysis showed that MNPs were encapsulated into polymeric
NPs with a carbonyl stretch peak at 1745 cm-1 corresponding to the ester bond in PLA
(Figure 5.2A). Thermogravimetric analysis (TGA) was used to quantify the relative
weight percent of polymer composition of PolyMNP formulations. By varying the
MNP:polymer weight ratios at 1:1.85, 1:5, and 1:10, we achieved 20, 25, and 33 wt%
polymer, respectively (Figure 5.2B). The degradation kinetics for the two polymers used
for encapsulation, PLA-PEG and PLGA(75/25)-PEG, were obtained via gel permeation
chromatography (GPC). Results indicated a variance in polymer degradation based upon
polymer composition (Figure 5.3). PLGA(75/25)-PEG molecular weight (Mw) decreased
faster compared to PLA-PEG, losing roughly 18% of its initial Mw after 2 weeks in PBS
at 37 °C due to its copolymer composition and higher hydrophilicity [49, 50]. PLA-PEG
lost approximately 3% of its initial Mw under the same conditions. By tailoring the
degradation kinetics of polymeric NPs, it is possible to control the MNP degradation rate
due to the increased content of oligomer residues from polymer degradation at the
interface of iron oxide MNPs and the polymer coating. Polymeric microparticles and
nanoparticles have been observed to degrade over time, forming a local acidic
microenvironment generated from degradation byproducts including lactic and glycolic
acid. The formation of a local acidic core within polymeric NPs has been shown [48,
51].

Furthermore, Miller et al. confirmed that lactic acid (0.1 M), a degradation

byproduct of PLA, led to dissociation of iron oxide after 100 hours at room temperature,
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demonstrating roughly 80% degradation at pH 3.5 but only 10% degradation at pH 5.5
[43]. However, other studies have shown that the use of lactic acid (0.12-0.16 M) to
expose cells to pH 5.7 or below induced cell toxicity [52].

Therefore, the use of

polymeric NPs to encapsulate MNPs permits the control of a local acidic
microenvironment within the degrading polymer NP that will in turn accelerate
encapsulated MNP degradation.
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Figure 5.1. Iron Oxide Degradation. (A) MNPs were encapsulated within polymeric
NPs prepared using conventional nanoprecipitation method. Two different polymers,
PLA-PEG and PLGA(75/25)-PEG, were used to prepare PolyMNPs. As both degrade at
different rates, they generate a differential content of polymer degradation byproducts
such as lactic acid and glycolic acid. (B) A schematic of the dissolution of iron oxide by
acids, specifically by polymer degradation byproducts lactic acid and glycolic acid,
which occurs in three primary steps: adsorption of organic ligands on the iron oxide
surface, non-reductive dissolution, and finally reductive dissolution [44].
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Figure 5.2. PolyMNP Characterization. (A) Using PLA-PEG NPs, polymer
encapsulation of PolyMNPs was tested for three MNP:polymer ratios: 1:1.85, 1:5, and
1:10. FT-IR showed the presence of PLA-PEG for all three formulations of the
PolyMNP assembly compared to the non-encapsulated MNP control. (B)
Thermogravimetric analysis was performed to determine the polymer:MNP content.
Results showed that the lowest MNP:polymer ratio (1:1.85) correlated to the highest
MNP content (80 wt% MNP), while the highest MNP:polymer ratio (1:10) corresponded
to the lowest MNP content (63 wt% MNP).
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Figure 5.3. Polymer Degradation. Polymer degradation analysis was performed for
both polymers used for PolyMNP encapsulation. Of the two polymers examined,
PLGA(75/25)-PEG degraded the fastest (green), losing 18% of its initial molecular
weight after two weeks in PBS at 37 °C. PLA-PEG (blue) demonstrated a slower
degradation rate, losing 3% of its initial molecular weight under identical conditions.
Statistical analysis indicated significant differences between the two polymers after three
days (* p < 0.05).
5.3.2. PolyMNP Degradation
The encapsulation of MNPs within polymeric NPs accelerated MNP degradation,
and MNP degradation was controlled by varying the polymer composition. Using 1:5
PolyMNP conditions, the degradation of MNPs encapsulated into both PLGA(75/25)PEG and PLA-PEG NPs was measured after incubating PolyMNPs within cellular
spheroids [47]. Briefly, PolyMNPs cellular spheroids were first treated with 5 N HCl to
dissociate MNPs within cellular spheroids, followed by quantification of the free iron
within the HCl solutions using a Perl’s Prussian blue colorimetric technique. PolyMNP
degradation was compared to non-encapsulated MNP degradation over the course of 28
days. PLGA(75/25)-PEG PolyMNPs demonstrated a 21% degradation of the initial iron
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content, while PLA-PEG PolyMNPs showed only a 12% degradation and non-coated
MNPs only a 7% degradation over the same time period (Figure 5.4A). These results,
which correlate with the polymer degradation rates (Figure 5.3), showed that the
PLGA(75/25)-PEG degraded more quickly than PLA-PEG. Polymer degradation is in
part controlled by the differential hydrophilicity in the polymer composition. Increasing
the polymer degradation rate is expected to more rapidly increase the content of the
acidic monomer and oligomer byproducts at the MNP interface [48, 49, 53]. Conversely,
a slower degradation of polymers is expected to slowly degrade MNPs due to a lower
content of acidic monomer and oligomer byproducts. The degradation of PolyMNPs was
further qualitatively confirmed by histological staining of cellular spheroids over the
course of 40 days using H&E and Lillie’s Turnbull Reaction to highlight iron oxide
MNPs (Figure 5.4B, PLA-PEG PolyMNPS Figure 5.5). Results showed that similar to
non-encapsulated MNPs, PolyMNPs dissociate over time into smaller aggregates of
MNPs, a dissociation that corresponds to a degradation of the MNPs shown in Figure
5.3A [41]. PolyMNP degradation studies were also performed using PLGA(50/50)-PEG
PolyMNPs in cellular spheroids (Figure 5.6), as well as using all three polymers in PBS
(Figure 5.7A). A primary concern of using MNPs for tissue engineering is their longterm presence in human tissues, with often adverse effects. A safe method that can
accelerate this MNP degradation, however, is expected to limit the interaction of MNPs
with the biological environment, which is critical in reducing cytotoxicity. The presented
results confirm that the polymer composition of PolyMNPs can control the degradation
rate of MNPs in physiological conditions. This accelerated degradation, compared to
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non-encapsulated MNPs, makes PolyMNPs most appealing for use as MNPs in
biomedical applications that necessitate limited interaction with the biological
environment.
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Figure 5.4. Effect of Polymer Composition on PolyMNP Degradation. (A) Two
polymers possessing different degradation rates were used to prepare PolyMNPs: PLAPEG and PLGA(75/25)-PEG. A Perl’s reagent (potassium ferrocyanide) assay was used
to measure the degradation of PolyMNPs encapsulated into both polymer nanoparticles
after incubation of PolyMNPs within cellular spheroids [47]. An analysis of that
degradation within cellular spheroids showed that polymer degradation rates mediate
MNP degradation. PLGA(75/25)-PEG PolyMNPs, the fastest degrading polymer of the
two formulations tested, demonstrated the most accelerated MNP degradation compared
to PLA-PEG PolyMNPs and non-encapsulated MNP controls over the course of 28 days.
Statistical analysis showed significant differences (* p < 0.05) after two weeks compared
to raw MNPs. (B) Degradation of PolyMNPs was also qualitatively analyzed using
histological staining (H&E and Lillie’s Turnbull for Iron) over the course of 40 days.
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Results showed that PolyMNPs dissociate into smaller aggregates over time, correlating
with quantitative MNP degradation analysis (Scale bar = 500 µm).
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Figure 5.5. PLA-PEG PolyMNP Degradation in Cellular Spheroids. Histological
analysis of cellular spheroids containing PLA-PEG PolyMNPS confirmed the
degradation of MNPs over the course of 40 days. Degradation was demonstrated by
dissociation of MNPs into smaller aggregates over time. Results were confirmed with
H&E and Lillie’s Turnbull Reaction to visualize iron oxide dissociation. Scale bar = 500
µm.
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Figure 5.6. PLGA(50/50)-PEG PolyMNP Degradation. (A) Polymer degradation
analysis confirmed that PLGA(50/50)-PEG polymer degraded with time, losing 5% of its
initial MW after 14 days in PBS at 37 °C. (B) PolyMNPS were assembled using
PLGA(50/50)-PEG NPs and a MNP degradation analysis within cellular spheroids
showed that these PolyMNPs resulted in a 16% reduction in initial iron content after 28
days.
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Figure 5.7. PolyMNP Degradation in PBS. The degradation of MNPs within
PolyMNPs was also analyzed in PBS at 37 °C. (A) The effect of polymer composition on
PolyMNP degradation was assessed using three different polymers: PLA-PEG,
PLGA(75/25)-PEG, and PLGA(50/50)-PEG. PolyMNPs were assembled using 1:5
MNP:polymer reaction conditions. Results showed that similar to PolyMNP degradation
in cellular spheroids, PLGA(75/25)-PEG PolyMNPs resulted in the highest MNP
degradation, losing 11% of its initial iron content after 28 days. PLA-PEG and
PLGA(50/50)-PEG PolyMNPs resulted in 3% and 5% loss of initial iron content after 28
days, respectively, while raw MNPs lost only 1% of their initial iron content. Statistical
analysis showed significant differences for all samples compared to raw MNPs (* p <
0.05) at all time points except PLGA(50/50)-PEG at day 7. (B) The effect of
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encapsulation efficiency on PolyMNP degradation was also analyzed in PBS. Similar to
PolyMNP degradation in cellular spheroids, PLA-PEG PolyMNPs were used for all
reaction conditions. Results showed that similar to degradation in cellular spheroids,
PolyMNPs assembled with the highest encapsulation efficiency (1:10) resulted in the
most accelerated MNP degradation, demonstrating 64% loss of their initial iron content
compared to raw MNPs which lost only 16% of their initial iron content. PolyMNPs
assembled using 1:5 and 1:1.85 reaction conditions resulted in losses of 62% and 33% of
their initial iron content, respectively. Statistical analysis showed significant differences
for all samples compared to raw MNPs (* p < 0.05) at all time points except 1:1.85 at two
and three weeks. However, a statistically significant difference was seen again for 1:1.85
samples at four weeks.
The effect of polymer content to PolyMNP degradation was subsequently
analyzed. By varying the relative content of polymer encapsulating MNPs within
polymeric NPs, we controlled the rate of MNP degradation. By increasing the content of
polymer, we created less MNPs within the polymeric NPs and accelerated MNP
degradation (Figure 5.8). As mentioned earlier, TGA results showed that by varying
MNP:polymer weight ratios during synthesis (Figure 5.2B), we controlled the content of
polymer encapsulation of MNPs. Having a higher content of polymer encapsulating
MNPs within NPs is expected to increase MNP degradation because of the higher content
of monomer and oligomer degradation byproducts [54]. Therefore, the results suggest
that the increased presence of degradation byproducts accelerates MNP degradation [48].
Specifically, in experiments using cellular spheroids with PolyMNPs prepared with 1:10
(lowest loading, 33 wt% polymer) and 1:1.85 (highest loading, 20 wt% polymer), we
observed a 74% and a 10% reduction of their initial iron content after 28 days,
respectively. These results indicate that MNP degradation can be tailored by both
polymer composition and content. PolyMNP degradation using various encapsulation
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efficiencies was also performed in PBS, demonstrating the same trend shown in cellular
spheroids (Figure 5.7B).
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Figure 5.8. Effect of Polymer Content on PolyMNP Degradation. Using PLA-PEG
PolyMNPs, a degradation analysis was performed to determine the effect of polymer
content on MNP degradation. The degradation of PolyMNPs composed of 1:1.85 and
1:10 MNP:polymer ratios was analyzed over the course of 28 days in cellular spheroids
using a Perl’s reagent assay [47]. Results showed that PolyMNPs with the highest
polymer content (1:10) correlated to the most accelerated degradation over the course of
28 days, because of the increase in monomer and oligomer degradation byproducts within
polymeric nanoparticles. Statistical analysis indicated significant differences (* p < 0.05)
between the two samples after two weeks.
5.3.3. PolyMNPs in Cellular Spheroids
Since magnetic cellular spheroids are used as components in tissue engineering
applications to assemble complex tissues via magnetic force assembly [55-57], which
causes prolonged MNP and cell interactions, we analyzed PolyMNP cytotoxicity.
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PolyMNPs assembled using PLA-PEG and PLGA(75/25)-PEG polymeric NPs were
incorporated into magnetic cellular spheroids and analyzed for cytotoxicity over a period
of two weeks. PolyMNPs, 0.5 mg/mL, maintained high viability until the end of that
time for both PolyMNP formulations, compared to control spheroids without MNPs
(Figure 5.9A).

Furthermore, compared to spheroids composed of cells which

internalized raw MNPs, PLGA(75/25)-PEG PolyMNP spheroids maintained a high
viability compared to control spheroids without MNPs up to one week (Figure 5.10).
Raw MNP spheroids showed viability below 20%, compared to control spheroids.
Viability studies were also performed at lower PolyMNP concentrations of 0.15 mg/mL
(Figure 5.11), demonstrating no adverse effects on cellular spheroids viability up to two
weeks.

Additionally, magnetic cellular spheroids with PolyMNPs were used to

magnetically pattern and assemble fused tissues (Figure 5.9B). Tissue rings, 2 mm in
diameter, were successfully patterned and assembled using both PolyMNP formulations,
with an equivalent fusion compared to non-encapsulated MNPs.

Magnetic cellular

spheroids containing PolyMNPs were magnetically patterned and fused together over the
course of 48 hours, with fused tissue observed after the removal of the magnetic template.
These results demonstrated that PolyMNPs maintain high cellular viability and promoted
fusion, suggesting that PolyMNPs are a biodegradable alternative to non-encapsulated
MNPs for tissue engineering applications.
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Figure 5.9. PolyMNPs Integrated Within Cellular Spheroids. (A) The effect of
PolyMNPs on cellular spheroid viability was analyzed to determine the suitability of
PolyMNPs for prolonged cellular interaction. Results showed that PolyMNPs (0.5
mg/mL) can be incorporated into cellular spheroids and maintain high viability compared
to MNP-free controls for up to two weeks. Statistical analysis showed significant
differences (* p < 0.05) compared to control spheroids without MNPs for PLA-PEG
samples at one and two weeks, but in favor of PolyMNP spheroids (normalized ratio
greater than 100%). PLGA(75/25)-PEG spheroids showed significant differences at all
time points, with viability increasing compared to controls at one and two weeks. (B)
Furthermore, PolyMNP-containing cellular spheroids were magnetically patterned and
assembled into fused tissue rings. Twenty-five individual PolyMNP spheroids were
patterned and fused over the course of 48 hours, at which point the magnet pattern was
removed and the samples imaged. Results showed a fused tissue construct, confirming
that PolyMNPs can be used to assemble fused tissue rings with equivalent fusion
compared to non-encapsulated MNP controls. Scale bar = 1,000 µm.
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Figure 5.10. PolyMNP Spheroid Viability. Compared to control cellular spheroids
without MNPs, PLGA(75/25)-PEG PolyMNPs maintained high viability over the course
of one week. Cellular spheroids assembled using cells which had internalized raw MNPs
(non-coated) showed significantly reduced viability (* p < 0.05), demonstrating viability
below 20% compared to MNP-free controls.
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Figure 5.11. Effect of PolyMNPs on Cellular Spheroid Viability. The effect of
PolyMNPs on cellular spheroid viability was analyzed to determine the suitability of
PolyMNPs for prolonged cellular interaction. Studies were performed at lower PolyMNP
concentrations (than those previously reported). Results showed that PolyMNPs (0.15
mg/mL) can be incorporated into cellular spheroids and maintain high viability compared
to MNP-free controls for up to two weeks. Statistically significant differences were seen
at one week (* p < 0.05), but in favor of PolyMNP spheroids (normalized ratio greater
than 100).
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5.4. Conclusions
Results showed that the degradation of MNPs can be controlled by the polymeric
microenvironment. It was further demonstrated that the degradation rate of MNPs within
cellular spheroids can be controlled by varying the polymer composition and content of
PolyMNPs. Additionally, high cell viability was maintained in magnetic cellular
spheroids up to two weeks, which is a most desirable characteristic of these spheroids for
use as constituents for tissue engineering applications requiring prolonged interaction
between MNPs and cells. Finally, PolyMNP spheroids were magnetically patterned to
promote fusion into homogenous tissues, confirming that magnetic force assembly can be
used to pattern PolyMNPs.

These results demonstrated that the polymeric

microenvironment could be used to precisely control the degradation of MNPs in
physiological conditions, which will limit the interaction of MNPs with cells.
Consequently, this process is invaluable in creating methods to use MNPs in medical
applications, in drug delivery, and as bioimaging agents composed of iron oxide. Future
research will entail the use of different polymers for PolyMNP encapsulation, an analysis
of the molecular changes at the interface between MNPs and polymers, and a study of the
degradation of macrostructures.
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CHAPTER 6
CONCLUSIONS
Nanotechnology can improve upon current biomedical strategies by mimicking
the native biological structure at a sub-cellular level. While MNPs have been
incorporated into tissue engineering strategies to provide in situ imaging, drug delivery,
and tissue patterning, the direct and prolonged interaction of MNPs with cells can induce
adverse effects on cell viability, phenotype, and function, and therefore remain a critical
concern. Consequently, methods to reduce any adverse effects and interaction of MNPs
with cells will benefit tissue engineering strategies requiring prolonged interaction. Key
challenges encountered when integrating nanotechnology, particularly MNPs, into tissue
engineering strategies include: 1) internalization of NPs into cells, 2) mediating subcellular interactions during tissue assembly, 3) complex chemical modifications to
improve biocompatibility of NPs, and 4) prolonged interaction between NPs and cells.
The presented results demonstrate that a variety of methods can be used to improve upon
the use of MNPs within tissue engineering. Using cellular spheroids as a model, results
showed that MNPs can be safely and effectively incorporated into tissue engineering
strategies.
6.1. Janus Magnetic Cellular Spheroids to Reduce MNP Internalization
Cellular spheroids have been investigated as tissue engineered building blocks
due to their ability to mimic the native 3D cellular and ECM structure of tissues [1-4].
Magnetic forces can be utilized to pattern and manipulate cellular spheroids for assembly
of complex tissues, with a variety of methods used to incorporate MNPs within cellular
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spheroids [5-11]. Common methods include internalization into cells [12-15], dispersion
throughout the ECM space [5, 12, 16], or conjugation to the cellular membrane [7, 11,
17]. While these have proven effective in short term studies, adverse effects regarding
cell viability and phenotype are encountered due to internalization of MNPs within cells
[5, 6, 15, 17, 18]. We developed a novel method to incorporate MNPs within cellular
spheroids possessing two segregated domains, one composed of cells and the other of
extracellular MNPs. We hypothesized that this separation of MNPs and cells would limit
the interaction of MNPs and cells, thereby avoiding adverse effects on cell viability and
phenotype. Compared to cellular spheroids assembled using cells that have internalized
MNPs (Uptake spheroids), JMCSs maintain high long-term viability and stable
phenotype expression compared to MNP-free controls. Viability was maintained using a
variety of ECM compositions, contents, cell types, and cell densities, confirming that this
technique can be applied to assemble tailored tissues for desired applications. Other
groups have shown adverse effects on spheroid viability at iron oxide MNP
concentrations of 50 µg/mL [6] and adverse effects on cell phenotype at 240 µg/mL [19].
However, the presented results used iron oxide MNPs at 300 µg/mL for all cell viability
and phenotype studies (unless otherwise noted), a concentration higher than that reported
by other groups while avoiding any adverse effects. Furthermore, while other groups
have dispersed MNPs throughout the entire extracellular space of cellular spheroids [5,
12, 16], the presented Janus technique localizes MNPs into a segregated extracellular
region, which further limits the interaction between MNPs and cells. The rationale for
studying this is to understand the effect of MNPs and magnetic cellular spheroid
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composition on cell viability and phenotype expression. These results confirm that the
method by which MNPS are incorporated into cellular spheroids is critical for effective
and safe tissue engineering strategies. Furthermore, the presented Janus technique can
serve as an effective method to incorporate MNPs into cellular spheroids while avoiding
adverse effects common to MNP internalization.
Cell

+

MNP

+

ECM

Common Magnetic Cellular Spheroid
Dispersed

Uptake

Novel Janus Magnetic
Cellular Spheroid
Janus

Figure 6.1. Decreased Interaction between MNPs and Cells using Janus Magnetic
Cellular Spheroids. Decreased interaction between MNPs and cells resulted in improved
cell viability and phenotype expression, avoiding adverse effects that often occur due to
MNP internalization into cells.
6.2. Promoting and Mediating Spheroid Fusion via Magnetic Force Assembly
Although cellular spheroids fuse together when placed within contact of each
other, methods to align and maintain spheroids in a set location in 3D are needed before
complex tissues can be fabricated. Methods to pattern and align spheroids include: direct
seeding into a mold [20, 21], printing into a hydrogel or biopaper [2, 22, 23], or surface
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patterning to promote adhesion [24-27]. Although these are effective, they require
complex material fabrication or modification to be functional, therefore limiting their use
in large-scale tissue engineering strategies. The use of magnetic forces to manipulate and
align cellular spheroids can be utilized for this patterning and expanded into tissue
engineering. Magnetic force assembly and patterning is appealing for tissue engineering
as it allows for action at a distance and can be easily patterned and controlled using solid
or custom magnetic fields. Once we demonstrated that MNPs could be incorporated into
cellular spheroids while avoiding adverse effects related to their internalization, we
utilized JMCSs to assemble and manipulate cellular spheroids into controlled patterns
and complex tissues. We hypothesized that JMCSs could be utilized to assemble tailored
complex tissues using magnetic force assembly. Results showed that using magnetic
force manipulation, JMCSs could be assembled into a variety of controlled patterns
regardless of shape or size. Next, results demonstrated that magnetic forces can be used
to mediate fusion of cellular spheroids into more complex tissues, confirming that it is
critical to control magnetic forces used during tissue assembly. Using a vascular tissue
construct as a proof of concept, thousands of JMCSs were successfully assembled into
tailored complex tissues. Other groups have demonstrated assembly of vascular tissue
constructs using printed bioink [22] or cellular spheroids [21]. Tissue tube assembly with
printed bioink showed variations in tissue fusion throughout the constructs [22]. The
presented results confirm that magnetic forces mediate and accelerate spheroid fusion.
Kelm et al. showed that the application of fluid flow to the lumen of the fused tissue led
to an increased fusion of assembled spheroids into a tissue tube after 14 days [21]. Here,
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we demonstrated that by applying magnetic forces during fusion, we can effectively
control the fusion of JMCSs into a single fused tissue without fluid flow. The rationale
for these studies is that magnetic forces can be used to align JMCSs into a controlled
pattern and drive their fusion by maintaining these JMCS in close contact with one
another, thereby accelerating and enhancing spheroid fusion compared to unpatterned
assembly. Results highlight that a variety of factors mediate spheroid fusion into complex
tissues, and care must be taken to optimize these parameters based on desired outcomes.
JMCSs

Cell + MNP + ECM

Cell MNP

Tissue

ECM

Figure 6.2. Promoting Spheroid Fusion using Magnetic Force Assembly. Results
showed that magnetic forces could be used to promote the fusion of JMCSs into complex
tissues, with magnetic force properties mediating their fusion into homogenous tissues.
6.3. Biological Magnetoferritin NPs to Improve MNP Biocompatibility
A variety of MNPs have been investigated for imaging, drug delivery, and tissue
patterning techniques, but commonly investigated biomedical MNPs are limited due to
adverse effects on cells [5, 6, 15, 17, 18]. These metallic MNPs often involve complex
surface modification to improve or reduce cytotoxic effects [28, 29]. Therefore,
magnetoferritin, a biological MNP derived from ferritin, was investigated as a biological
alternative to inorganic iron oxide MNPs. We hypothesized that magnetoferritin NPs
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could be synthesized with tailored magnetic properties and serve as a biologically based
MNP for tissue engineering applications. Results showed that we could tailor the loading
and magnetic properties of magnetoferritin NPs, and safely incorporate them into cellular
spheroids without any adverse effects on cell viability. Furthermore, magnetoferritin
cellular spheroids were magnetically patterned and fused into controlled patterns using
magnetic force manipulation. Other groups have utilized magnetoferritin NPs for tumor
targeting [30] and cell sorting [31]. The presented results demonstrate the use of
magnetoferritin NPs into tissue engineering applications. Furthermore, while others have
shown toxic effects of iron oxide MNPs at 50 µg/mL [6], the presented results show that
spheroids assembled using cells which had internalized magnetoferritin NPs at 500
µg/mL showed no adverse effects on cell viability up to one week. The rationale for these
studies is that inorganic MNPs often require complex chemistry to improve or reduce
cytotoxic effect on cells, and that the biological nature of magnetoferritin NPs will
improve upon MNP biocompatibility in tissue engineering applications.

Results

demonstrated that magnetoferritin NPs can serve as a biological alternative to inorganic
iron oxide MNPs, mitigating the cytotoxicity that prevents the use of MNPs in tissue
engineering applications.
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Figure 6.3. Tailored Magnetic Properties of Biological Magnetoferritin NPs. Results
showed that magnetic properties of magnetoferritin NPs could be tailored and improve on
the biocompatibility of common iron oxide MNPs. Magnetoferritin NPs were
incorporated into magnetic cellular spheroids with no adverse effects on cell viability,
and were capable of magnetic force assembly for tissue engineering applications.
6.4. Accelerated MNP Degradation via Polymer Encapsulation
The prolonged presence of MNPs can induce adverse effects in cells, causing cell
toxicity, and changes in both cell phenotype and cell mobility [6, 14, 19]. Though the
surface functionalization or coating of MNPs in oleates [32, 33], dextran [34, 35], or
polymers [36, 37] can improve MNP biocompatibility, they do not control the MNP
degradation. Ideally, MNPs will remain stable for a sufficient time to accomplish their
desired task, and then rapidly degrade once their task is completed. Therefore, we
developed a method to accelerate the degradation of iron oxide MNPs via encapsulation
within polymeric NPs. By encapsulating MNPs within polymeric NPs, we hypothesized
that MNP degradation could be mediated by the local acidic microenvironment generated
by polymeric NP degradation. Results showed that PolyMNP degradation could be
tailored based on polymer content and composition. PolyMNPs were assembled using
multiple biodegradable polymers, with results confirming control over MNP loading
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within polymeric NPs. To confirm their capacity for tissue engineering applications,
PolyMNPs were incorporated into cellular spheroids and maintained high viability up to
two weeks. Furthermore, PolyMNP cellular spheroids were patterned and fused into
controlled shapes using magnetic force assembly. Groups have demonstrated that surface
functionalization or coating can enhance MNP biocompatibility and functionality by
improving cell viability, uptake, or biodistribution [37], but these techniques often
involve complex chemistry and do not necessarily accelerate the removal of MNPs from
the body. The presented technique offers a simplistic method to encapsulate MNPs within
a biocompatible polymer that actively accelerates the degradation of MNPs. This
technique requires no chemical modifications to MNPs and can be expanded to a variety
of different NPs or polymers compositions for various applications. Furthermore,
although studies have shown that lactic acid can accelerate MNP degradation at an acidic
pH (pH 5.5 and below) [38], the pH required for degradation with these acids has been
confirmed to induce toxic effects on cells (pH 5.7 or below) [39]. The presented results
utilize the capacity of NPs to control the pH of the local microenvironment and accelerate
MNP degradation via polymer degradation byproducts [40]. The rationale for these
studies is to limit the interaction between MNPs and cells that is common to tissue
engineering applications by accelerating the degradation of MNPs. These results
demonstrated that the polymeric microenvironment could be used to control the
degradation of MNPs in physiological conditions. This technique can be applied to
strategies beyond tissue engineering to limit the interaction of MNPs with the biological
environment.
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Figure 6.4. Accelerated MNP Degradation. The degradation of MNPs was accelerated
by encapsulation within polymeric NPs. Results showed that PolyMNPs could be
assembled with tailored polymer content and composition, with MNP degradation
dependent on polymer degradation rate and MNP loading.
6.5. Summary
The presented results highlight multiple strategies which can improve upon the
biocompatibility of MNPs in tissue engineering applications. Results emphasize that
limiting the internalization of MNPs within cells is critical to avoiding adverse effects on
cell viability and phenotype. A variety of strategies including spatial segregation of
MNPs away from cells, use of biologically-based MNPs, or decreasing the amount of
interaction between MNPs and cells via accelerated degradation can be applied to
common tissue engineering strategies to assemble complex tissues. While common tissue
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engineering strategies which utilize internalization of MNPs within cells are effective in
short-term, their prolonged interaction with cells limits their use in the development of
functional engineered tissues capable of long-term use. Using a small diameter vascular
construct as a platform, we have developed a broad range of nanomaterial strategies for
tissue engineering which improve upon current MNP techniques.
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CHAPTER 7
RECOMMENDATIONS

Based on the literature review and the limits of the presented results, a summary
of future recommendations includes:

7.1. Analyses and Development of Methods to Induce JMCS Elastin Synthesis
While the ECM is composed of a variety of biomolecules, collagen and elastin
provide critical structural and mechanical support for tissues [1, 2]. Additionally, the
ability of cellular spheroids to secrete their own ECM makes them appealing for tissue
engineering applications [3]. Preliminary results showed that the addition of MNPs to
JMCSs promoted collagen synthesis within cellular spheroids compared to MNP-free
controls. Next, it would be interesting to study the effect of MNPs on JMCS elastin
synthesis, or develop methods to induce elastin synthesis within JMCSs. While MNPs
alone may not induce elastin synthesis, treatment of JMCSs with chemical or growth
factors may induce or accelerate its synthesis. A variety of chemical and growth factors
including TGF-!1 [4], aldosterone [5], insulin [6], hyaluronic acid [7], and retinoic acid
[8] have been shown to accelerate or induce elastin synthesis and should therefore be
investigated with JMCSs.
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7.2. Effect of JMCS Composition on Spheroid Fusion
Tissue printing techniques have been applied to assemble tailored complex
tissues, but these tissues often encounter issues with incomplete or inconsistent fusion
throughout [9-12]. Results showed that the magnetic force properties used during
magnetic force assembly were critical in mediating JMCS fusion. Therefore, future
studies should be performed to determine the effect of other spheroid parameters, such as
ECM composition, content, and cell density, to determine their effect on JMCS fusion.

7.3. Assembly & Maturation of Various Tissues using JMCSs and Magnetic Force
Assembly
Companies, such as Organovo, have utilized cellular spheroids to assemble
biomimetic engineered tissues for use in therapeutic screening and disease modeling
technologies, including the fabrication of a 3D liver tissue model. Our results confirmed
that JMCSs could be assembled with a variety of ECM and cellular compositions and
contents while avoiding adverse effects on cell viability. Therefore, JMCSs can be
tailored to assemble a variety of tissues types based on target tissue native ECM and
cellular compositions. The ability to control magnetic patterning will allow for the
assembly of muticellular tissues with precise control over the spatial location of various
JMCS types. Furthermore, MNPs distributed throughout assembled tissues could be
utilized to induce tissue maturation using mechanical stretching via magnetic force
manipulation. A variety of tissues, including skeletal muscle, cardiac, bladder,
respiratory, digestive, and vascular tissues, require constant mechanical stretching within
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the body to function. However, diseases and conditions such as atherosclerosis, muscular
dystrophy, aneurysms, and pulmonary fibrosis interfere with a tissue’s natural ability for
mechanical stretching, eventually leading to tissue failure. These diseases and conditions
highlight the critical requirement for constant mechanical stretching in native tissues.
Once engineered tissue constructs have been assembled, they often require additional
treatment to induce maturation and improve mechanical properties to more closely mimic
native tissues [13]. Mechanical stretching can be applied to improve the mechanical
properties of engineered vessels [14-17], and is often applied using custom bioreactors or
chemical treatments with histamine, potassium, noradrenaline, or serotonin [18, 19].
However, these strategies often involve long fabrication times (months), and are therefore
cost and time consuming [20]. Magnetic force maturation has shown success in
engineered bone constructs, inducing desired differentiation and ECM production with
short treatment times (1-3 weeks) [21, 22]. Furthermore, unlike fluid flow or chemical
maturation techniques which affect areas only in direct contact, magnetic maturation
offers the ability to manipulate the tissue construct throughout, affecting all cells.

7.4. Improved Magnetoferritin NP Magnetic Properties
Though a magnetic NP may possess some magnetic properties, this does not
necessarily correlate to application in magnetic force assembly. A magnetic NP must
possess sufficient magnetic properties to be capable of magnetic attraction and
manipulation within a functional magnetic field range. Studies have shown that
aggregates of magnetoferritin NPs possess increased magnetic characteristics compared
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to dispersed samples [23]. Our results showed that magnetoferritin NP magnetic
properties could be tailored based on loading. Therefore, work should be performed to
analyze other ways to increase the magnetic properties of magnetoferritin NPs via
aggregation. The use of crosslinking would provide control over the amount of
aggregation, with the additional benefit of being able to remove crosslinking via various
treatment techniques (chemical, heat, pH, etc.).

7.5. Additional Studies on Magnetoferritin NPs
Studies utilizing iron oxide MNPs demonstrated the capacity for JMCSs to
assemble complex 3D tissue using magnetic force assembly. Additionally, results showed
that magnetoferritin cellular spheroids could be magnetically patterned and fused into a
simple tissue ring. This work should be expanded to use magnetoferritin cellular
spheroids for the assembly of complex and multicellular 3D tissues using magnetic force
assembly, similar to previous studies done using iron oxide JMCSs to assemble a small
diameter vascular tissue construct.
A key concern with MNPs is prolonged interaction with cells, demonstrating
adverse effects on cell viability and phenotype [24-28]. Results analyzed the effects of
magnetoferritin NPs on cell viability up to two weeks, but this should be expanded up to
at least seven weeks similar to iron oxide JMCSs. Most tissue engineering applications
require prolonged interaction between cells and MNPs on the scale of weeks, making
long-term studies a key concern for effective application. Furthermore, studies should be
performed to analyze the effect of magnetoferritin NPs on phenotype expression.
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7.6. Additional Studies on PolyMNPs
Polymer degradation is mediated by a variety of factors including polymer
molecular weight and composition [29, 30], as well as environmental factors such as heat
and pH [31, 32]. Additionally, the degradation of different types of polymers will release
various degradation byproducts which in turn have various effects on the surrounding
microenvironment [33]. Results showed that three different biocompatible polymers
composed of PLA, PLGA, and PEG could be utilized to assemble PolyMNPs and induce
accelerated MNP degradation. It would be interesting to assemble other PolyMNPs
composed of other polymeric components to determine the overall ability to control MNP
degradation via polymer selection.
The degradation of MNPs occurs via chelation of surface iron [34]. Results
showed that encapsulation of MNPs within polymeric NPs accelerates degradation, and
we proposed a mechanism by which this occurs. Therefore, studies should be performed
to analyze what is actually occurring at the surface of MNPs within PolyMNPs during
degradation to determine various parameters that can be tailored to further accelerate
degradation. This could lead to optimization of PolyMNP systems which could further
accelerate MNP degradation.
As mentioned prior, the degradation of polymeric NPs and MNPs is dependent on
a variety of local and environmental factors, with studies showing differences between
the in vivo and in vitro rates of polymer degradation [35]. Studies confirmed that MNP
degradation was accelerated in vitro in both PBS and cellular spheroids. Therefore, these
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studies should be expanded to in vivo degradation to ensure that MNP degradation is still
accelerated using PolyMNPs compared to raw MNPs.
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